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“We must not forget that when radium was discovered no one knew that it would prove useful in 
hospitals. The work was one of pure science. And this is a proof that scientific work must not be 
considered from the point of view of the direct usefulness of it. It must be done for itself, for the 
beauty of science, and then there is always the chance that a scientific discovery may become like 
the radium a benefit for humanity.” 
Marie Skłodowska-Curie 1867-1934, Nobel Prize in Physics 1903, Nobel Prize in Chemistry 1911.  
 
 
 
“When bubbles settle on the surface of the urine, they indicate disease of the kidneys, and that the 
complaint will be protracted.” -- Hippocrates 400 BC.   
  
ABSTRACT 
 
Background: Chronic kidney disease (CKD) affect up to 10-15% of the population 
worldwide and is a growing global health problem. Diabetes, hypertension and renal diseases, 
such as glomerulonephritis, are the major cause of CKD in high- and middle-income 
countries. CKD is a strong independent risk factor for cardiovascular disease (CVD) and 
CKD patients do worse after a cardiovascular event. This is only partially explained by 
traditional risk factors. Several non-traditional risk factors for CVD in CKD are becoming 
recognised, such as inflammation, oxidative stress, calcium-phosphate metabolism, 
endothelial dysfunction, malnutrition, anemia, and most recently gut microbiota, all in 
interplay with accumulating uremic toxins as renal function decline. 
Hemostatic disturbances including platelet dysfunction are well known in CKD, which is 
considered a prothrombotic state. However, the paradoxical simultaneous increased risk of 
bleeding is less understood. Microparticles (MPs) are small sized vesicles (100-1000 nm), 
which are shed into the circulation from various cells including platelets and endothelial cells 
due to different stimuli or apoptosis. MPs carry the same surface proteins as their parent cell, 
and MPs are both markers of disease and can induce inter-cellular cross talk. Platelet MPs 
(PMPs) are the most abundant MPs in the circulation, and the major significance is their 
procoagulant activity. MP concentrations are known to correlate with both CKD and CVD.  
Vitamin D deficiency and endothelial dysfunction is evident early in CKD and are associated 
with increased risk of CVD. Normal endothelial function is essential for maintained 
hemostasis. Vitamin D is involved in calcium-phosphate balance and upregulates production 
of nitric oxide, essential in endothelial function. Endothelial microparticles (EMPs) may have 
a role in assessing endothelial dysfunction.  
The overall objective of this PhD project was to elucidate some of the complex mechanism 
causing CKD patients to suffer such high risk for CVD, with focus on hemostatic 
disturbances, and platelet and endothelial microparticles. 
Methods and results:  
In study I, hemostasis was studied using a global assay in patients with severe CKD, patients 
on hemodialysis, and healthy controls The results demonstrated a prothrombotic state and an 
impaired fibrinolysis in severe CKD, as well as a tighter fibrin network assessed with 
scanning electron microscopy, despite normal concentrations of endogenous fibrinolysis 
inhibitors.  
In study II, platelet and endothelial microparticles were investigated in acute coronary 
syndrome (ACS) patients with and without CKD, using flow cytometry. PMPs and EMPs 
concentrations were elevated in severe CKD 
Study III, a substudy of the SOLID randomized placebo-controlled trial, where paricalcitol 
treatment in CKD patients demonstrated beneficial effects on endothelial function and 
reduced proinflammatory cytokines. In our study, paricalcitol treatment reduced 
concentrations of intercellular adhesion molecule-1 (ICAM-1) positive MPs. Concentrations 
of cell-activation induced EMPs and PMPs were maintained in the paricalcitol group.  
Study IV investigated if biomarkers related to hemostasis, endothelial function and vascular 
regulation correlated with renal function in a large cohort of ACS patients, and determined 
  
their association with outcome in the subgroups with preserved and with reduced renal 
function. Biomarkers were quantified by proteomic methods. The biomarkers in ACS patients 
with reduced renal function indicated a prothrombotic state, with altered endothelial function 
and vascular regulation, and several of these were associated with outcome in this group. 
Conclusions: 
We confirm that CKD is associated with a prothrombotic state, and at the same time an 
impaired fibrinolysis potentially due to a tighter fibrin network. 
We show that in ACS patients with CKD, the MP profile indicate higher platelet activation 
and endothelial dysfunction compared with non-CKD patients, despite concurrent dual 
antiplatelet and statin treatment. 
We show that in CKD patients, paricalcitol treatment reduce concentrations of ICAM 
positive MPs, indicating a less proatherosclerotic endothelium. 
We found that in a large cohort of ACS patients with reduced renal function, the biomarker 
profile indicates a prothrombotic state. The biomarkers associated with outcome differ 
between patients with CKD and non-CKD. This indicate that in the field of biomarkers, it 
might not be sufficient to adjust for renal function. Rather, when renal failure is established, it 
could be regarded as a separate disease state with its own distinct pathophysiology. 
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LIST OF ABBREVIATIONS 
ACE angiotensin-converting-enzyme inhibitor 
ADP adenosin diphosphate 
AKI acute kidney injury 
AP angina pectoris 
AV- fistula/graft arteriovenous fistula/graft  
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FMD flow mediated vasodilation 
Fp fibrinolysis activation profile  
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HDF hemodiafiltration 
HDL high-density lipoprotein 
HF heart failure 
HRPR high residual platelet reactivity  
HT hypertension 
ICAM-1 intercellular adhesion molecule-1 
LDL low-density lipoprotein 
MDRD Modification of Diet in Renal Disease (MDRD) Study 
MI myocardial infarction 
  
MP microparticles 
N-STEMI non-ST elevation myocardial infarctio 
NO nitric oxide 
PAR-1 protease activated receptor-1 
PCI percutaneous coronary intervention 
PECAM platelet adhesion cell adhesion molecule 
PD peritoneal dialysis 
PMP platelet derived microparticles 
PSGL-1 P-selectin glycoprotein ligand-1 
RAAS renin-angiotensin-aldosterone system 
RCT randomized controlled trial 
RRT renal replacement therapy 
STEMI ST-elevation myocardial infarction 
suPAR soluble urokinase plasminogen activator receptor 
TAFI thrombin activatable fibrinolysis inhibitor 
TxA2 tromboxan A2 
tPA tissue plasmin activator 
uPA urokinase plasminogen activator 
VCAM vascular cell adhesion molecule 
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1 INTRODUCTION 
1.1 CHRONIC KIDNEY DISEASE 
In 1836 Dr Richard Bright at Guy´s Hospital, London, England, wrote Cases and 
observations illustrative of renal disease (1). Dr Bright had noticed several patients suffering 
from a disease he described as “mottling”. This disease often came after an episode of 
scarlatina, or in patients with episodes of hematuria in younger age. The patient became 
swollen, dropsy1 and discovered their urine was tinged with blood. The doctor noticed the 
urine contained albumin by heating the urine in a teaspoon over a light of fire and noticed the 
amount of precipitate; the albumin (2). The pulse was “full and hard” (1).  
Dr Bright noticed that in several cases, as years passed, the patients’ health inexorably 
declined. They suffered increasingly fatigue, headache, vomiting, their healthy color 
disappeared and the examination of the blood showed presence of urea. These symptoms and 
signs came and went, the swelling likewise, and after a period of time the patient’s status 
deteriorated and they eventually fell into coma and died. As Dr Bright wrote, “the painful 
history of this disease is closed” (1), and he was convinced this disease was somehow related 
to the albuminuria.  
Today we know that Dr Bright accurately described glomerulonephritis, acute or chronic, 
leading to chronic kidney disease (CKD) and end stage renal disease. 
CKD is a globally growing health problem, affecting 10-17% of the general population. 
Diabetes mellitus and hypertension are the major risk factors for CKD as well as various 
types of “Bright’s disease”, i.e. glomerulonephritis (3). The prevalence has been rising for 
decades, but the increase seems to be slowing down since the middle of 2000. The 
explanation of this is complex, where an increased life expectancy contribute to an age-
                                                 
 
 
1 Dropsy: old-fashioned term for oedema. Swedish: Vattusot    
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related increase in prevalence, while better treatment of hypertension, diabetes and changes in 
life-style contribute to a decrease (4).  
CKD has climbed on the list of causes of global death, from 27:th place in 1990, to 18:th 
place 2010, and in 2016 CKD was ranked 11:th, according to the Global burden of disease 
study (5). The increase is particularly seen in low- and middle-income countries.  
Chronic kidney disease is one of the strongest risk factors for cardiovascular disease (CVD), 
and in fact, most CKD patients die from cardiovascular disease and not from end-stage renal 
disease (6). 
1.2 CLASSIFICATION OF CHRONIC KIDNEY DISEASE 
The Kidney Disease Global Outcomes (KDIGO) define CKD as reduced glomerular filtration 
rate and evidence of kidney damage (albuminuria) persistent for 3 months. In CKD 1-2 there 
has to be evidence of kidney damage to fulfil the criteria for CKD (7). Based on this there are 
five stages of CKD (8-10). 
 
 
Table 1. CKD classification according to international guidelines. 
Chronic kidney disease CKD stages  eGFR Frequency % 
ml/min/1.73 m2 
1  Normal renal function with signs of kidney damage* >90 4.0  
2  Mildly impaired renal function* 60-89 3.2  
3a 
T** 
Mildly to moderately impaired renal function 45-59 
6.2 
4.7 
3b Moderately to severely impaired renal function 30-44 1.5 
4  Severely impaired renal function 15-29 0.4  
5 D** Kidney failure (End stage renal disease)  <15 0.1  
Chronic kidney disease (CKD) defined as abnormalities of kidney structure or function, present for >3 months. 
* Albuminuria present 
**Add suffix T if patient is kidney transplanted, D if patient is on dialysis.  Frequency % in the population 
eGFR estimated glomerular filtration. 
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1.3 ESTIMATION OF RENAL FUNCTION 
The estimated glomerular filtration rate (eGFR) can be calculated from a number of equations 
based on creatinine concentrations. The Cockcroft-Gault formula estimates creatinine 
clearance without correction for body surface area, and thus calculate the absolute value of 
filtration (11). The MDRD equation from The Modification of Diet in Renal Disease 
(MDRD) Study 1999 (12), revised 2006 provided an improved equation and related eGFR to 
body surface area 1.73/min/min, but was less reliable in older patients, i.e.in  m2 over 70 
years of age (13). The CKD-EPI Chronic Kidney Disease Epidemiology Collaboration 
formula was developed and implemented after 2014 and provides more reliable eGFR 
estimates in all adults (14). Both the MDRD and CKD-EPI formulas include age, gender and 
race in the equation calculated from creatinine and there is consensus they are both superior 
to the Cockcroft-Gault to estimate renal function. In Sweden, the Revised Lund-Malmö GFR 
estimating equation is calculated from both creatinine and cystatin C and is considered 
superior in a Swedish population (15). 
1.4 CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISASE 
Dr Bright noticed in the autopsies of several patients, a remarkable left ventricular 
hypertrophy, without any signs of valvular disease. He stated “The two most ready solutions 
(for this hypertrophy) appear to be either that the altered quality of the blood affords irregular 
and unwanted stimulus to the organ immediately; or that it so affects the minute and capillary 
circulation as to render greater action necessary to force the blood through the distant 
subdivisions of the vascular system”(2). Bright discovered that renal disease could cause 
cardiovascular disease, but he did not know the mechanisms behind it.  
Today we consider already mild to moderate CKD to be an independent predictor of all-cause 
mortality and cardiovascular mortality in the general population (16). In the 2016 “European 
guidelines on cardiovascular disease prevention in clinical practice”, the risk prediction score 
for a 10-year risk of fatal CVD, classify CKD at an eGFR below 60 ml/min/1.73 m2 as high-
risk, and eGFR below 30 ml/min/1.73 m2 as very high-risk, in the same risk group as patients 
with a previous myocardial infarction or stroke (Figure 1)(17). 
The increase in premature CVD and the poor outcome after a CVD event in CKD patients is 
caused by a complex interplay between several pathophysiological mechanisms. Platelet 
 4 
 
dysfunction and hemostatic disturbances both contributes to the very last step in the 
pathophysiology in CVD: the formation of a thrombus and is therefore of particular interest 
in CKD.   
Figure 1. Estimated 10-year risk of future cardiovascular death 
based on risk factors and co-morbidities (17) Used by permission 
from European Heart Journal. 
 
1.4.1 Traditional and non-traditional risk factors 
This greatly increased risk of CVD in CKD patients is only partially explained by high 
prevalence of the traditional Framingham risk factors such as smoking, dyslipidemia, 
hypertension, advanced age, diabetes and obesity (18). Patients with CKD have the traditional 
risk factors for CVD to a great extent, partly because the impaired renal function itself can be 
a manifestation of the atherosclerotic burden. However, non-traditional risk factors such as 
endothelial dysfunction, oxidative stress, inflammation, malnutrition, anemia, 
hyperhomocysteinemia, abnormal calcium-phosphate metabolism and hemostatic 
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disturbances, all have been shown to contribute to the increased risk of CVD in patients with 
CKD (19). These metabolic and inflammatory alterations, contributing to the accelerated 
vascular disease are induced by, or amplified by, retention of a range of organic compounds 
termed uremic toxins, which normally are metabolized or excreted by the kidney (20). Thus, 
the traditional risk factors are of relatively less importance in more advanced renal failure (19).  
1.4.2 Uremic toxins 
Impaired renal function leads to retention of a range of organic products, uremic toxins, e.g. 
tryptophan-derived uremic toxins (TDUT) such as indoxyl sulfate, indole-3-acetic acid 
(IAA), kynurenine (KYN), anthranilic acid (AA), and p-cresyl sulfate, trimethylamine-N-
oxide (TMAO), all normally metabolized or excreted by the kidney. Over 90 different 
compounds have been identified, and they are often classified according to their solubility 
and size: small molecules with a molecular weight (MW) below 500 Dalton, middle 
molecular weight compounds (MW between 500 and 12,000 Dalton) and high molecular 
weight compounds (> 12,000 Dalton). Smaller, water-soluble compounds are easily removed 
by highly permeable hemodialysis filters while protein-bound molecules are difficult to 
remove (20).  
Another way to classify uremic toxins is based on their origin. Uremic toxins can be 
produced by endogenous metabolism, which is the majority of the uremic toxins, or by 
microbial metabolism from protein degradation, such as phenolic and indolic short-chain 
fatty acids, ammonia, amines, and thiols, which all are potentially toxic, or they can be 
ingested, e.g. oxalate or advanced glycation end-products (20). Uremic toxins contribute in 
various ways to both progression of CKD and to the pathophysiology of CVD by 
proinflammatory, profibrotic mechanisms, such as in vitro demonstrated inhibition of  NO 
production, stimulation of vascular smooth muscle cell proliferation in the vessel wall, 
hereby, all of this contributing to development of atherosclerosis (21, 22). 
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1.4.3 Gut microbiota, a putative risk factor for CVD 
Gut microbiota is becoming recognized as a risk factor for CVD and atherosclerosis (23, 24). 
In CKD patients, uremic toxins accumulate and affect the gut microbiota composition and 
metabolism, which further contribute to production of more uremic toxins, as previously 
discussed. Several of these toxins are associated with altered hemostasis, atherosclerosis and 
increased platelet reactivity (25, 26). These toxins impair endothelial function (27), and may 
cause vascular and renal toxicity (22), and are associated with outcome in CKD patients (21, 
28). Heianza et al concluded in a meta-analysis from 2017 in Journal of American Heart 
Association that metabolites from gut microbiota in humans were independently associated 
with risk of CVD and all-cause mortality (29). It was also demonstrated that gut microbiota 
composition in humans related to blood pressure (30). Another study in humans published in 
Nature 2013, showed that obese persons had less diversity of bacteria composition compared 
to non-obese individuals, and an inflammatory phenotype (31). Gut microbiota also affects 
the immune system by influencing the differentiation of T-cell-subsets, and a “healthy” 
microbiota may shift these towards less pathogenic circulating T cells (Foxp3+ Tregs), 
suppressing immune processes involved in atherosclerosis (32). Mice models raised in a 
sterile environment demonstrate unaffected initial platelet adhesion, but significant less 
platelet aggregation, reduced thrombosis growth, and lower concentration of von Willebrand 
factor (vWf) compared with mice whit normal gut flora (33). A novel study from 2018 
demonstrated that transplantation of gut microbiota from humans to mice, can alter the 
generation of specific uremic toxins, depending on the gut microbiota composite transplanted, 
altering platelet in vitro aggregation and reactivity, as well as in vitro thrombus formation 
(34). Recent data also supports that Vitamin D can affect the gut microbiota both in mice and 
human (35), and also that loss of muscle mass, and the concept of physical frailty in elderly 
persons might have a relation to the gut microbiota composition (36). 
In short, gut microbiota is altered in CKD patients (25, 26), it seems to have a role in early 
mechanisms in atherosclerosis and CVD (22, 27, 29), it is involved in immune system 
modulations (34), it seems to affect hemostasis, and transplantation of gut flora has the ability 
to alter hemostasis (34). It is tempting to speculate that gut flora might contribute to CKD 
patients increased risk of CVD, but this is far beyond the scope of this thesis. 
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1.5 THE CARDIORENAL SYNDROME 
Kidney disease and cardiovascular disease, both acute and chronic, interact in a complex 
manner. Atherosclerosis can cause both renal impairment and ischemic heart disease. 
Impaired heart function may cause decreased kidney perfusion (37).  
 
 
 
Figure 2. The type 4 cardiorenal syndrome, “chronic renocardiac syndrome”.  
Reprinted from Cardiorenal syndrome by Claudio Ronco et al. 2008 (37). Journal of the American 
College of Cardiology, with permission from Elsevier. 
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Decreasing renal function accelerates atherosclerosis by several mechanisms, and in severe 
renal failure, the accumulation of uremic toxins and volume overload more directly impair 
heart function (38). 
The cross-talk between the heart and the kidneys has such a dignity that it can really be 
considered a clinical syndrome. In 2008, Dr Claudio Ronco published one of the first 
comprehensive classification of the cardio renal syndrome (CRS) (37).  
The syndrome embraces several of the disturbances listed above and both traditional and non-
traditional risk factors. These all contribute to premature vascular ageing and early CVD in 
these patients. The initial classification has recently been more clearly defined and used to 
stratify outcomes in clinical trials (38). An integrated view of this syndrome will guide 
clinicians in designing future clinical trials, and hopefully towards multidisciplinary teamwork 
of cardiologists, nephrologists and nurses, to provide better care in this patient group (39). 
 
 
 
Table 2. Cardiorenal syndrome, classification, modified from American Heart Association (38). 
Classification Description Description Clinical example 
Type 1 CRS Acute CRS HR resulting in AKI ACE, acute HF 
Type 2 CRS Chronic CRS Chronic HF resulting in CKD Chronic HF 
Type 3 CRS 
Acute renocardiac 
syndrome 
AKI resulting in acute HF 
HF in the setting of AKI 
from volume overload 
Type 4 CRS 
Chronic renocardiac 
syndrome 
CKD resulting in chronic HF 
CKD associated HF and 
cardiomyopathy 
Type 5 CRS Secondary CRS 
Systemic disease resulting in 
HF and kidney failure 
Liver cirrosis, amyloidosis, 
sepsis 
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1.6 HEMODIALYSIS TREATMENT 
The Scottish chemist Thomas Graham already in 1850 made the first scientific contribution 
to dialysis by his discovery of diffusion and osmosis (40, 41). In the early 20th century, there 
were attempts to perform hemodialysis on humans without success on survival.  It took until 
1945, when Dr Willem Kolff from the Netherlands managed to treat a patient with acute renal 
failure to full recovery (42, 43). The hemodialysis was further developed and refined in the 
40´s and 50´s and Dr Nils Alwall Sweden is generally recognized as the inventor of the first 
practical dialysis machine (44). 
Currently over 2 million people in the world, mostly in developed countries, receive renal 
replacement treatment (RRT), as dialysis or kidney transplant, to stay alive (45).  
Dialysis treatment is performed either as peritoneal dialysis or as hemodialysis. In peritoneal 
dialysis, the dialysis fluid is introduced and maintained in the abdomen through a permanent 
catheter. Uremic toxins and excessive fluid diffuse from the blood, over the peritoneal 
membrane into the dialysis fluid, which is exchanged 3-4 times daily by the patient. In 
hemodialysis, the blood passes through an external dialyzer with a semi-permeable 
membrane where toxins and fluid can be removed. Each session last 3-4 hours and is repeated 
preferably at least 4 times weekly, at home during either the day or night, if the patients have 
the ability to learn the procedure, otherwise as in-centre treatment. The optimal hemodialysis 
regimen is an ongoing debate: frequent shorter five times weekly, or daily dialysis, or 
overnight longer dialysis sessions. However, it clearly seems that the still commonly 
prescribed regimen of three times weekly is the least favorable (46). 
Maintenance hemodialysis treatment is challenging from several aspects; the vascular access, 
the bio incompatibility of the materials in the dialyzers, endotoxins in dialysis fluid, micro-air 
embolism, ultrafiltration rate, length of each dialysis session, inter dialytic weight gain and 
many more (46). Adding a convective component by using hemodiafiltration to mimic the 
filtration in the glomeruli for better removal of so called “middle sized molecules” is 
suggested to prolong survival on hemodialysis, but data is still incongruent (46, 47). Several 
factors not directly related to the dialysis procedure, such as team-based care with a person-
centered approach, patient education, access to physiotherapy, dieticians, social workers and 
other support services are also of great importance for the patients to endure this demanding 
life-supporting chronic treatment (48). 
Hemodialysis patients are in a constant pro-inflammatory state, due to the past chronic renal 
failure exposure, the inability of the dialysis to completely replace a normal kidney, and to 
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the dialysis procedure per se(49) . This contributes to the concept of protein-energy wasting 
(PEW) state, described as a progressive loss of muscle mass and energy reserves. PEW in 
hemodialysis patients is associated with a further increased risk of CVD (50). Hemodialysis 
treatment is also closely associated with both bleeding, anemia and with arterial, venous and 
vascular access thrombosis (51).  
1.7 ENDOTHELIAL DYSFUNCTION AND VASCULAR 
CALCIFICATION 
The endothelium consists of a single cell layer of endothelial cells that line the inside of the 
blood vessels and is a vital organ system that closely and intricately interacts with platelets, 
the coagulation and immune systems. It consists of 700 gram tissue with a surface-size of a 
soccer field (6000 m2) (52). The healthy endothelium expresses a balanced production of 
substances involved in vascular tone, platelet activation, coagulation and immune responses. 
Nitric oxide (NO) is an important vasoactive substance produced by endothelial cells, 
essential for maintaining vascular homeostasis (53). The endothelium produces multiple 
substances, platelet adhesion molecules such as P-selectin, leucocyte recruitment molecules 
E-selectin, intercellular adhesion molecule (ICAM), vascular cell adhesion molecule 1 
(VCAM), vWf, profibrinolytic factors such as tissue plasminogen activator (tPA), urokinase 
plasminogen activator inhibitor (uPAR),thrombomodulin and fibrinolytic inhibitors such as 
plasminogen activator inhibitor 1,(PAI-1) (53-55).  
The endothelial dysfunction in the early atherosclerosis process is characterized by impaired 
endothelium mediated vasodilatation, and a shift towards “activated” endothelial cells 
expressing substances and surface receptors that interact and activate inflammatory cells, 
causing chronic vasoconstriction and a procoagulant state (56, 57). As endothelial 
dysfunction and atherosclerosis advance, this result in a functional stiffening of the arteries 
which contributes both to accelerated CVD and to the progression of renal dysfunction (56). 
Vascular calcification affects the intima or media in the vessel wall in two separate and often 
parallel processes: atherosclerosis with plaque development, and arteriosclerosis with 
vascular stiffening and calcifications (58). The atherosclerotic process with the inflammatory 
plaque in its more advanced stages also causes vascular calcification.  
Atherosclerosis starts early, often already in adolescence (59), but is accelerated by 
hypercholesterolemia, hypertension, smoking, diabetes, i.e. all the established Framingham 
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risk factors (60). In more advanced CKD, the dominant form of vascular calcification is the 
media sclerosis, also known as Mönckebergs sclerosis (58). The calcification involves 
primarily the intima media layers of the vessels and is related to the duration of dialysis, 
presence of hyperphosphatemia and the calcium-phosphate balance. Media sclerosis is no 
longer considered a passive biochemical process, rather it involves smooth muscle cells, 
whom under influence of the uremic milieu transform to express osteoblasts markers, and 
they to some extent become bone cells (58). 
1.8 VITAMIN D AND CHRONIC KIDNEY DISEASE  
Vitamin D deficiency is common in CKD patients due to loss of the available enzyme 1,25-
hydroxylase, which activates 25-OH-vitamin D to 1,25-dihydroxyvitamin D. Lack of active 
vitamin D causes hypocalcemia, by decreased absorption of calcium from the gut, and 
decreased reabsorption of calcium filtered in the kidney.  Low calcium concentrations 
stimulate release of parathyroid hormone (PTH), and vitamin D is widely used in CKD to 
treat secondary hyperparathyroidism and prevent CKD mineral bone disorder (MBD) (61, 
62). 
Short-term treatment studies with active vitamin D have shown beneficial effects with 
reduction of proteinuria, reduction of inflammatory cytokines, and preserved macrovascular 
function assessed by flow-mediated dilatation (FMD) (63-65). FMD measure the capacity of 
the brachial artery to dilate, after ischemia induced by a pneumatic tourniquet. The 
vasodilation is measured at certain time points, and the relative change of the diameter of the 
artery is determined. The largest randomized controlled trials using vitamin D in CKD were 
the PRIMO trial (66) and the OPERA trial (67), both failed to demonstrate beneficial effects 
on left ventricular mass index. However, both PRIMO and OPERA studied whether vitamin 
D treatment could regress left ventricular mass in patients with more advanced CKD. It is 
plausible to argue that potential effects of vitamin D treatment or supplementation would be 
of more benefit earlier in the disease development, and be related to endothelial and vascular 
function, not myocardial structure.  
In summary, there are indications of beneficial effects of Vitamin D treatment on endothelial 
function, but there is lack of large RCTs to demonstrate outcome as hard endpoints such as 
progression of kidney disease or mortality. Studies on the effects of vitamin D treatment in 
CKD on microparticles have not been previously been performed.  
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1.9 PLATELET FUNCTION 
Platelet activation is considered to be the initial step in hemostasis and can be induced by 
endothelial injury exposing subendothelial collagen, fibronectin, tissue factor(TF) and vWf, 
or soluble platelet activators which, interact with various receptors on the platelet (68). When 
platelets are activated they release platelet activating substances from dense and alpha 
granules including ADP, serotonin (69) and P-selectin, CD40ligand (CD40L) (70) and they 
also synthesize and release thromboxane A2, a potent vasoconstrictor and platelet activating 
compound (70). This leads to modifications of the receptor GPIIb/IIIa, towards a high affinity 
state stimulating platelet aggregation. GPIIb/IIIa is regarded as the most important receptor 
for platelet aggregation (68). The platelets also change shape from a discoid form to a form 
with pseudopodias leading to increased membrane surface that adhere to the endothelium. 
Thromboxane A2 mediates an important enforcement of platelet aggregation by binding to the 
receptor on the surface on the platelets (71) . The action of thromboxane is limited due to the 
short half-life (68). There are multiple signaling pathways all reinforcing platelet aggregation 
by positive feedback mechanisms. All of this together with a simultaneous release of 
microparticles expressing phosphatidylserine, possibly also carrying TF, trigger the blood 
coagulation process (68). GP Ib-IX-V has high affinity for thrombin (72), linking the first 
wave of hemostasis, which is the phase were platelets adhere and aggregate, with the second 
wave of hemostasis where the coagulation cascade is activated. TF further triggers platelet 
activation by forming complexes with active FVII, causing activation of FX and ultimately 
generating thrombin, which is a very potent platelet agonist, generated locally on the surface 
of activated platelets. Thrombin-induced platelet activation is elicited through the protease-
activated receptor-1 (PAR-1) as described below. 
ADP, released by activated platelets, interacts with P2Y12 receptors on surrounding platelets 
leading to further platelet aggregation (68). P-selectin, an adhesion molecule expressed on a 
variety of cells but mainly activated platelets and endothelial cells, is involved in cellular 
interactions causing proinflammatory and prothrombotic effects (73). The main receptor for 
P-selectin is P-selectin glycoprotein ligand-1 (PSGL-1), expressed on leucocytes and 
endothelial cells. P-selectin is shedded from the cell surface and soluble P-selectin is 
considered a marker for platelet activation (70). 
The CD40-CD40L system connects the platelet, the coagulation and the immune 
systems(74). CD40L is a transmembrane protein, expressed mainly on activated platelets, and 
platelets are also the main source of the soluble form sCD40L. The receptor CD40 is found 
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on a variety of cells, platelets, immune cells such as T cells, neutrophils, and endothelial cells. 
In platelets CD40L mediate the stability of the thrombus(70). Interaction of CD40L with the 
receptor CD40 expressed on endothelial cells, both resting and activated, promote expression 
of adhesion molecules such as E-selectin, vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1)(75). 
The protease-activated receptors are a class of receptors, where the PAR-1 is most important 
type of PAR receptor on human platelets (76). Notably, PAR-1 is a thrombin specific 
receptor that can activate platelets at lower concentrations than required to fully activate the 
coagulation cascade. Platelet PAR-1 activation results in platelet activation with release of 
other platelet activating factors like thromboxane A2 and ADP (76).  
There is new and interesting knowledge on the role of micro RNAs in platelet signaling. 
Platelets do not have a nucleus with DNA, but still carry genetic information as microRNA 
from their parent megakaryocyte. MicroRNAs are small non-coding strands of RNA that can 
regulate gene expression when transferred to other cells. Hundreds of microRNAs are 
identified in platelets and their role in CVD and as biomarkers for platelet function are being 
investigated (77).  
 
 
Figure 3. Overview of receptors involved in platelet function. Large circles are platelets. Microparticles budding 
from the platelet. Josefin Mörtberg/Biorender.com.  
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1.10 HEMOSTATIC DISTURBANCES IN CKD 
Hemostasis is the delicate state that can stop local bleeding without clotting the entire 
circulation. It is a complex system with multiple parallel processes involving the vascular 
endothelium and subendothelium, platelets, the coagulation cascade finally generating 
thrombin and insoluble cross-linked fibrin, and the fibrinolytic system. 
There is a range of hemostatic disturbances reported in CKD, see Table 3. Based on clinical 
experience and previous research, CKD is considered a prothrombotic (78) and 
hypofibrinolytic state (79). The paradox that CKD patients have a high risk of thrombosis 
while at the same time suffer an increased risk of bleeding is not well understood, but 
underpin the importance of a well-balanced hemostatic system.  
 
Table 3. Hemostatic disturbance described in CKD. 
Hemostasis factors  grouped according to function 
Pro-coagulation Fibrinogen (FI) increased (80-85) 
TF (FIII, former thromboplastin) increased (78, 80-82, 86) 
Factor VIIa increased (78, 80, 82, 83), 
Factor X decreased (78) 
Von Willebrand factor increased (81-83, 86, 87) 
Factor XIIa increased (80, 82) 
Factor VIII increased (81, 83, 85, 88, 89)  
Factor V no difference (83) 
APTT (activated partial thromboplastin time) 
(prekallikrein, FXII, FXI, FIX, FVIII, FX, FV, prothrombin, 
fibrinogen) 
no difference (83) 
PT prothrombin time/PK/INR( international 
normalized ratio) ( extrinsic pathway F II-
prothrombin, FVII, FX) 
no difference(83) 
Weakens coagulation Antithrombin activity reduced (78, 80) 
no difference (87) 
AT III (antithrombin III) no difference (83) 
TF pathway inhibitor (TFPI) increased (81) 
Protein C CKD 5 decreased (83) 
Active Protein C increased (80) 
Protein S no difference (83) 
Anticoagulant 
properties 
Soluble thrombomodulin increased (81, 84, 86, 88, 90) 
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Inhibit fibrinolysis TAFI no difference (87) 
PAI-1, plasminogen activator inhibitor increased (82, 84, 85) 
no difference (81, 86)  
increased in CKD + CVD (91) 
PAI-1 antigen decreased (87) 
PAP plasmin-antiplasmin complex increased (81) 
Fibrinolysis activators tPA reduced (80)   
increased in CKD+CVD (91) 
tPA ag/ tissue plasmin activator ag increased (84)  
plasminogen  
Markers of fibrin 
turnover 
D-dimer increased (80, 81, 83, 84) 
Global methods 
Fibrin network 
structure 
Fibrin network denser (87) 
denser in CKD + CVD (91) 
Fibrin clot denser in CKD + CVD (92, 93) 
Global methods Fibrinolysis potential decreased (87) 
Euglobulin clot lysis time/ fibrinolytic activity impaired fibrinolysis (79) 
Thromboelastography, fibrinolytic kinetics, clot lysis 
time 
impaired fibrinolysis (94) 
Thromboelastography, coagulation kinetic analysis increased coagulation (83, 94) 
Occlusion time reduced (95) 
Lysis time impaired (95) 
APTT(activated partial thromboplastin time) 
(prekallikrein, FXII, FXI, FIX, FVIII, FX, FV, FII-
prothrombin, fibrinogen) 
no difference (83) 
PT prothrombin time/PK/INR(international 
normalized ratio) (extrinsic pathway FII-
prothrombin,FVII, FX) 
no difference (83) 
Markers of fibrin 
turnover 
D-dimer increased (80, 81, 83, 84) 
Thrombin-anti thrombin complex increased (80, 84) 
Prothrombin fragment 1+2  increased (78) 
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1.10.1 Coagulation 
The first step in the coagulation cascade is initiated either by the extrinsic or the intrinsic 
pathway (96). Activation by the extrinsic pathway is triggered when FVII encounters TF, 
forming a complex that further activates FIX and FX. The intrinsic or contact activation 
pathway is initiated when prekallikrein and high-molecular-weight kininogen binds to a 
surface, activating FXII (Hageman factor) to FXIIa which in turn activate FXI and further 
activate the cascade (96).  
The intrinsic pathway is likely not as essential for hemostasis as the extrinsic system, as 
patients with deficiencies in the intrinsic pathway (e.g. FXII deficiency) do not have severe 
bleeding disorders (97). The last step in the coagulation cascade, independent of the 
activation pathway, is the conversion of plasma fibrinogen to an insoluble fibrin clot. 
CKD patients suffer an increased risk of both arterial thrombosis as well as deep venous 
thrombosis and pulmonary embolism (98, 99). In hemodialysis patients the most common 
thrombotic event is thrombosis in their life supporting dialysis access; the arteriovenous  
(AV-) fistula or graft (51). 
There are some similarities, but also some differences between a venous and an arterial 
thrombosis. Arterial thrombosis occurs in the system with high blood flow and is more 
dependent on direct platelet aggregation after vessel damage and subendothelial exposure. 
Venous thrombosis occurs in the low flow system, and are more dependent on the 
coagulation system. The concept of Virchow’s triad: change in blood flow such as stasis or 
turbulence, endothelial damage or dysfunction, and a hypercoagulable state, is important in 
all thrombosis mechanisms (57). Venous thromboses are loosely bond to the vessel wall and 
contain entrapped red blood cells, which make them red or dark in color. In contrast, the 
arterial thrombus is mainly built up by platelets, fibrin, white blood cells, and are whiter in 
color and usually more firmly attached to the injured vessel wall or plaque. Interestingly, 
CKD patients with acute coronary syndrome (ACS) have denser fibrin clots assessed by 
permeation assays, and denser clot structure has been related to mortality in ESRD (91, 93). 
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1.10.2 Fibrinolysis 
The central step in fibrinolysis is the conversion of the inactive circulating proenzyme 
plasminogen to plasmin. Insoluble fibrin within the hemostatic clot or thrombus is degraded 
by plasmin into fibrin degradation products. There are two major plasminogen activators: 
tissue-type plasminogen activator (tPA) and urokinase type plasminogen activator (uPA), of 
which tPA is considered the most important and its activity profoundly increased in the 
presence of fibrin (100). The most important endogenous inhibitor of tPA and uPA is likely 
the plasminogen activator inhibitor (PAI-1) (80).  
Thrombin activatable fibrinolysis inhibitor (TAFI) is another important inhibitor of 
fibrinolysis (101). TAFI is activated by thrombin in the presence of thrombomodulin, and 
contributes to fibrin clot stability (100).  Other proteins with inhibitory effect on fibrinolysis 
are of importance for the stability of the fibrin clot, including alpha2-antiplasmin and 
complement C3 (100). Alpha-2-antiplasmin forms a complex with plasmin hereby 
inactivating it. In addition, FXIII crosslinks fibrin polymers to a more stable fibrin 
network(100). 
With respect to CKD, studies have indicated a hypofibrinolytic state in patients suffering 
impaired renal function, which has been associated with poor cardiovascular outcome (95). 
1.10.3 Bleeding in CKD  
The knowledge that CKD patients have an increased risk of bleeding goes back to 1764 
where Giambattista Morgagni in his book “Opera Omnia, Epistola Anatomico-Medica XLI”, 
Venice, Italy, described a renal patient with bleeding complications, “Sermo est de Urinae 
Suppressione” (102).  
This bleeding tendency with prolonged bleeding time is well known also for clinicians today 
taking care of CKD patients. It includes both mild bleedings such as nose bleeds, prolonged 
bleeding after vein puncture as well as life threatening bleedings from the gastrointestinal 
tract and an increased risk of intracranial hemorrhage (103). The early reports in the 1950´s 
focused mainly on platelet dysfunction in CKD patients(104). 
The platelet dysfunction observed in advanced CKD patients includes intrinsic platelet 
abnormalities such as defect intracellular granule content, altered platelet-vessel wall 
interactions and defect platelet aggregation caused by an impaired function of GPIIb/IIIa 
(82), as well as abnormal NO production (103). Many of these disturbances seems to be 
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caused by the uremic milieu itself, since some of them are reduced by dialysis (103), but 
despite that the bleeding tendency remains in dialysis patients (105).  
It has been proposed that elevated parathyroid hormone could contribute to the bleeding 
tendency (106). However, a study from 2016 demonstrated that parathyroid hormone did not 
affect platelet aggregation, in non-CKD patients with primary hyperparathyroidism compared 
with control (107), indicating that this does not contribute to the bleeding tendency.  
Normal endothelial function is dependent on the continuous release of NO as described above 
in chapter 1.7. NO inhibits platelet aggregation, and it has previously been shown that uremic 
plasma increase NO formation in vitro (108) which could contribute to a bleeding tendency.  
 Altered blood rheology due to anemia and lower hematocrit makes platelets flow in the 
center of the vessel, reducing platelet-vessel wall interaction, and hereby contributing to 
increased risk of bleeding (109). Correction of anemia with either erythrocyte stimulating 
agents, or blood transfusion improves symptoms and signs of prolonged bleeding (110). 
When evaluating bleeding in CKD patients, there are usually no disturbances noticed in 
routine laboratory markers such as platelet count, prothrombin time (PT), partial 
thromboplastin time (APTT)(82). Test of bleeding time is usually prolonged, due to the 
platelet deficiency (82). 
Microparticles might have a role in the increased bleeding tendency in CKD since one study 
has reported PMPs to correlate with bleeding in non CKD patients (111), were 
simultaneously the PMPs were increased. In CKD, most studies report of elevated 
concentrations of PMPs (Table 4) and in general PMPs are considered procoagulative (112-
114), so it is difficult to interpret that finding. 
The bleeding tendency in uremia is complex, multifactorial, and difficult to understand in the 
context of the simultaneously reports of CKD as a prothrombotic state (82, 85). Further 
studies are needed, and evaluation of the role of PMPs in the bleeding tendency in CKD 
would be of great interest.  
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1.11 MICROPARTICLES 
1.11.1 Microparticle discovery and classification 
In 1946, Dr Erwin Chargaff and Dr Randolph West reported that human platelet free plasma, 
created by extended centrifugation, promoted coagulation, indicating the presence of an 
additional clotting factor beside the known platelets (115). Twenty-one years later, in 1967, 
Dr Peter Wolf reported in The nature and Significance of Platelet Products in Human 
Plasma, that coagulant material originating from platelets, identified by electron microscopy, 
was this clotting factor. He called the material “platelet dust” (116). 
Today we know it as extracellular vesicles (EV), a term describing cell-derived membranous 
structures, surrounded by a phospholipid bilayer, without a cell nucleus and thus without 
ability to replicate. There is still not a clear definition of EV, and the classification is 
evolving, depending on size, markers on their surface or mechanisms of their release (117).  
A classification that is common today is into either apoptotic bodies/vesicles, exosomes with 
endosome origin or microparticles/microvesicles (118). In earlier research, the most common 
term for all EV was “exosomes”, important to know when studying the field, but today this 
term most often refers only to the smallest EV (119). In this Thesis the term microparticles is 
used. 
Microparticles (MPs) are small sized vesicles (100-1000 nm), circulating in plasma under 
normal conditions. They are shed from various cell types such as platelets, endothelial cells, 
and leucocytes by different biological stimuli, shear stress, or during apoptosis. MPs carry 
bioactive surface proteins originating from the parent cell, and they were initially considered 
mainly to be biomarkers of various disease, but later studies have shown that they have 
important biological effects and induce various biological responses (120).  
The most common method to study MPs is flow cytometry, and this technique is described in 
the methods part 3.2.2. Data on MPs are usually reported as counts, and monoclonal 
antibodies against surface proteins are used to identify their cellular origin, for instance 
platelet (GPIIb/IIIa; CD 41/61) or endothelial origin (platelet adhesion cell adhesion molecule 
[PECAM]; CD31), and activation state (e.g. P-selectin expression). 
Since many surface proteins are expressed on different cell types, MP specificity is often 
expressed as MPs positive for one marker and negative for another. For instance, 
CD31+/CD41- MPs, are MPs positive for PECAM, negative for GPIIb and thus considered 
to be an EMP. 
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1.11.2 Platelet microparticles 
Platelet derived MPs (PMPs) are the most abundant MPs in the circulation. They express 
several surface proteins and cytokines normally present on platelets, such as GPIb (CD42b), 
GPIX (CD42a), GPIIb/IIIa (CD41/61). The also express activation markers like P-selectin 
(CD62P), and CD40L (CD154), all involved in recruitment of inflammatory cells especially 
leukocytes and monocytes, inducing adhesiveness to endothelial cells and influencing 
hemostasis (120, 121). 
  
Table 4. Studies of microparticles in CKD. 
Authors Population Marker Results 
Mörtberg et al 
2019 (122) 
N=49; All ACS patients 
non-CKD, CKD 3,  
CKD 4-5 
CD62P+PMP ↑ in CKD 4-5 
CD40l+PMP ↑ in all CKD 
CD62E+EMP ↑ in all CKD 
Almquist et al 
2016 (123) 
N=39;   
Statin +/-Ezetimibe 
vs placebo 
All CKD 3-4;  +/- DM 
CD62P+PMP 
Baseline: ↑ in CKD 
Posttreat:↓ in CKD,↓nonCKD 
CD40l+PMP 
Baseline: ↑ in CKD, 
Posttreat: ↓ in all 
CD62E+EMP 
Baseline: ↑ in CKD 
Posttreat:↔ CKD,↑ non-CKD 
CD144+EMP 
Baseline: ↑ in CKD 
Posttreat: ↑ in all 
Chen 2015 
(124) 
N=88, CKD+AP,  
CKD+CAD, controls 
CD31+CD42b+PMP ↔ CKD 
CD31+CD42b-EMP ↔ CKD 
Burton 
2013(114) 
N=57;  
HD, PD, controls 
CD42b+PMP ↑ in CKD 
CD144+EMP ↑ in CKD 
Trappenburg 
2012 (125) 
N=37;   
CKD 4, PD, HD  
vs controls 
CD41+PMP ↑ in CKD 
CD62P+PMP ↑ in CKD 4, HD,↔PD 
CD144+EMP ↑ in CKD 4, HD, ↔PD 
Amabile 2012 
(126) 
N=81; HD.  
Follow up  
median 50 month 
CD41+CD31-PMP 
predicted all cause and CVD 
mortality 
CD31+CD41-EMP did not predict outcome 
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Dursun 2009 
(127) 
N=88; HD, PD, CKD 4 vs 
controls 
CD144+EMP ↑ in all CKD 
Boulanger 
2007 (128) 
N=34; HD  
correlation with shear 
stress in vivo 
CD41+CD31+PMP no correlation 
CD41-31+EMP Correlation 
CD144+ EMP Correlation 
Faure 2006 
(129)  
N=110;  
HD, CKD 4-5 vs controls 
(before HD session) 
CD41+PMP ↑ in CKD, ↔ HD 
CD144+EMP ↑ in CKD, ↑HD 
CD146+EMP ↑ in CKD,↑ in HD 
Amabile 2005 
(130) 
N=76; HD, controls 
(after HD session) 
CD41+CD31+PMPs ↑ in CKD not corr with FMD 
CD31+CD41-EMPs ↑ in CKD corr with FMD 
CD144+EMPs ↑ in CKD corr with FMD 
Ando 2002 
(131) 
N=118,  
CKD 4-5, HD, PD,  
controls (no DM) 
CD42+PMP ↑ in CKD 
 
One major functional significance of PMPs is associated with their procoagulant activity; 
PMPs can express phospholipids (the negatively charged phosphatidylserine (PS), on the 
outer surface, offering a negatively charged surface that promotes coagulation and fibrin 
formation to a much greater extent than activated platelets (112). PMPs can also carry TF, 
further contributing to their procoagulant properties (113), although the origin of TF may not 
be from platelets but rather other cells. 
The role of PS-negative MPs is not yet clear (132), but recent studies indicate that PS-
negative MPs are more common than previously reported (133). PMPs seem to have a direct 
effect on platelet aggregation and hemostasis (134), and in vitro they have the ability to make 
the fibrin clot more dense (135). 
Circulating PMPs are increased in numbers in various diseases such as ACS, diabetes 
mellitus, hypertension, asymptomatic arteriosclerotic lesion, and in CKD (118, 136). Platelet 
activation measured by expression of soluble P-selectin seems to be associated with the 
concentrations of PMPs in patients with ACS (137).  
In a study of non-ST elevation myocardial infarction (N-STEMI) patients without CKD, 
elevated concentrations of CD61 and CD62P+PMPs were found, as compared to healthy 
controls (138), and another study demonstrated CD62P+PMP could predict outcome(139). 
However, in yet another study, concentrations of CD41+PMPs were not significantly 
different in patients with STEMI without CKD, in comparison to healthy individuals, and 
their concentrations were not associated to outcomes (140). These conflicting results 
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demonstrates the need for further studies to evaluate the role of PMPs as potential biomarkers 
in MI. High concentrations of PMPs have been found to associate with the severity of 
myocardial infarction, in patients without CKD (141). Patients with ongoing clopidogrel 
treatment and high remaining platelet reactivity (HRPR), in in-vitro tests, have higher 
concentrations of PMPs compared with patients without HRPR, indicating a putative role for 
PMPs in evaluating treatment effect (142). Patients with NSTEMI treated with aspirin or 
statins did not differ in concentrations of PMPs, compared with patients without treatment 
(138). In CKD, the studies mostly report of elevated concentrations of MP (Table 4). The 
reason why is not clear but the uremia per se seems to contribute, since an in vitro study 
demonstrated that the uremic toxins p-cresol and indoxyl sulphate could increase 
CD146+EMPs from endothelial cells (129). 
1.11.3 Endothelial microparticles 
Endothelial microparticles are shed from activated or damaged endothelial cells. Several cell 
surface antigens are used to identify EMPs. In vitro studies demonstrate that MPs promote 
monocyte recruitment and adhesion to the endothelium and have the ability to impair 
endothelial function by decreasing NO production and by this mechanism, alter vascular tone 
(143). The markers chosen to identify EMPs are important when studying their relation to 
diseases. There are several endothelial cell markers such as the mandatory markers CD31 
(platelet endothelial cell adhesion molecule- PECAM-1), an adhesion protein involved in 
leucocyte migration, and CD144 (VE-cadherin) an endothelial cell specific molecule located 
in the intercellular junction important for vascular permeability and the extravasation of 
leucocytes, also involved in cell proliferation and apoptosis (143). CD31 and CD144 are 
considered markers of apoptosis induced EMPs, but there is still a lack of knowledge in 
which marker is best for identifying the different EMPs in various diseases (143).  
The inducible endothelial marker E-selectin (CD62E) is upregulated by cytokines in 
inflammation (52). It is an adhesion protein involved in recruitment and adhesion of platelets 
and leucocytes to the endothelial cell. Other inducible markers of endothelial activation are 
vascular cell adhesion molecules (VCAM-1; CD 106) and ICAM-1 (CD 54), both involved in 
leukocyte recruitment in the inflammation process in atherosclerosis (52, 144).  
Concentrations of CD31 and CD144 positive EMPs are known to increase in impaired 
vascular function assessed with flow mediated vasodilation and pulse wave velocity (143). 
EMPs can be considered a surrogate marker for endothelial dysfunction (126). EMP 
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concentrations are increased in a variety of diseases such as diabetes mellitus, heart failure, 
severe hypertension, ACS and CKD (130, 136), and increased concentrations are associated 
with worse outcome (145). 
1.12 ANTIPLATELET THERAPIES 
1.12.1 Acetylsalicylic acid  
The enzyme cyclooxygenase (COX) is needed for the conversion of arachidonic acid into 
thromboxane A2 and prostaglandins such as prostacyclin (146). Acetylsalicylic acid (ASA) 
inhibits cyclooxygenase 1 (COX-1) irreversibly, hereby diminishing the production of these 
substances (147), inhibiting platelet aggregation moderately. The importance of ASA in 
reducing cardiovascular event as secondary prevention was established first in 1987, in a 
large randomized, double blind, placebo controlled trial The Physicians' Health Study that 
was terminated in advance by the Data Monitoring Board, due to the marked risk reduction 
for recurrent myocardial infarction, noticed in the aspirin arm vs. placebo (148). ASA 
treatment is presently a cornerstone in secondary prevention together with P2Y12inhibitors in 
cardiovascular disease (149).  
1.12.2  P2Y12 inhibitors  
Blocking of the platelet ADP receptor results in a strong inhibition of platelet aggregation 
(150). ADP released from the platelets granulae at activation, strongly activates platelets both 
by autocrine and paracrine mechanisms, through the ADP receptor (151). This class of 
antiplatelet agents, the P2Y12 inhibitors, clopidogrel, ticagrelor and prasugrel, are commonly 
used as secondary prevention following a cardiovascular event.  
Genetic variability, diabetes and probably also CKD is associated to high residual platelet 
reactivity, the concept where some patients do not fully respond to clopidogrel as P2Y12 rec 
blockage. Impaired renal function did not explain HRPR in a European study but in a large 
Chinese study HRPR was associated with renal function (152, 153).  Recent studies support 
that newer P2Y12 ticagrelor is more potent than previously most commonly used clopidogrel 
(154). 
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1.12.3 GP IIb/IIIa receptor blockage  
GP IIb/IIIa receptor blockage inhibits binding of fibrinogen to the receptor and inhibits 
platelet aggregation. These types of drugs are administered intravenously, and are used 
predominantly when performing high-risk percutaneous coronary interventions (PCIs)(155, 
156). Orally administered GP IIb/IIIa receptor blockage were showed to be associated with 
increased risk of death but also bleeding when compared to aspirin (157, 158). In that study, 
the protocol was aspirin vs GP IIb/IIIa blockage, not adding it on top of aspirin. 
1.12.4 PAR-1 antagonists 
Locally generated thrombin acts on the protease activated receptor-1 (PAR-1), and hereby 
potently stimulates platelet activation. A potent antiplatelet drug class PAR-1 antagonist have 
also been developed (159). A large study of the PAR-1 receptor antagonist vorapaxar, added 
on to standard treatment as secondary prevention in stable patients with history of CVD, 
demonstrated a decreased risk of events, but unacceptable high severe bleeding 
complications, particularly intracranial hemorrhage (160, 161). 
1.12.5 Dipyridamole  
Dipyridamole is a phosphodiesterase inhibitor, where the main antiplatelet mechanism of 
action likely is through inhibiting adenosine uptake in red blood cells, platelets and 
endothelial cells, hereby increasing extracellular concentrations of ADP, which reduce 
platelet aggregation (162). Dipyridamole also increases endothelial NO signals, and stimulate 
release of prostaglandins from the vessel wall (162). Dipyridamole was used to achieve 
coronary vasodilation in the 1960: s.  However, the phenomena coronary steel, in high dose 
treatment, in which dilated resistance vessels directed blood away from the ischemic 
myocardium made this treatment a failure. Since then the role has primarily been for 
secondary prevention after stroke, now generally replaced by P2Y12 inhibitors added to 
aspirin (163). Recent studies of dipyridamole indicate other potentially beneficial anti-
inflammatory and antioxidant properties, including a possible future role in preventing 
proteinuria and preserving endothelial function, as well as a possible improvement in survival 
for CKD patients (162, 164). 
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2 AIMS OF THE PROJECT 
The overall objective of this PhD project was to elucidate some of the complex mechanisms 
causing CKD patients to suffer such high risk for cardiovascular events, by investing the role 
of hemostatic disturbances, platelet and endothelial microparticles in CKD and CVD, and 
evaluate if selected markers are associated with outcome in CKD patients. 
The specific objectives were: 
Study I 
To study whether the prothrombotic state in severe CKD is characterized by an increased 
fibrin formation, an impaired fibrinolysis or both, and to investigate the fibrin network 
structure. 
Study II 
To investigate whether patients with ACS and impaired renal function have further elevated 
concentrations of platelet- and endothelial microparticles, indicating more activated platelets 
and endothelial dysfunction, as compared to patients with preserved renal function.  
Study III 
To assess if paricalcitol treatment have beneficial effects on endothelium assessed by 
concentrations of endothelial microparticles expressing proatherosclerotic markers (ICAM-1 
and VCAM-1), as well as cell specific MPs, in a substudy of a randomized-controlled trial in 
CKD patients. 
Study IV 
To determine if concentrations of biomarkers related to hemostasis, endothelial function and 
vascular regulation correlate with renal function in ACS patients, and to assess if these 
biomarkers are of distinct prognostic importance in the subgroup of ACS patients with renal 
dysfunction.  
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3 MATHERIALS AND METHODS 
3.1 STUDY DESIGN AND POPULATION 
3.1.1 Study I 
In the cross-sectional study I we assessed hemostasis using a global assay, in patients with 
CKD 4, patients on hemodialysis, and healthy controls. 
Patients with CKD were recruited from the outpatient clinic and the hemodialysis unit at the 
Division of Nephrology, Danderyd University Hospital, Stockholm, Sweden. Exclusion 
criteria were ongoing treatment with vitamin K antagonists or active malignancy, and in the 
control group also past or present cardiovascular disease, active malignancy, chronic kidney 
disease, rheumatic disease, diabetes mellitus, and ongoing medication with any 
anticoagulants. Hypertension, treatment for hyperlipidemia and ongoing aspirin treatment 
were accepted. The control group was recruited from the Swedish national SPAR registry 
including all persons registered as residents in Sweden. The control group were selected to 
match age and sex with the CKD 4 and hemodialysis patients. The kidney function was 
determined by calculating the estimated glomerular filtration rate, eGFR, using the MDRD 
formula as ml/min/1.73m2, in the following abbreviated to ml/min. 
The aim was to assess hemostasis with a global method, which determine the amount of 
fibrin formed over time, fibrin optical density sum, and fibrin degradation, to determine if 
CKD was related to increased fibrin formation or degradation. Scanning electron microscopy 
also visualized the fibrin network structure in a randomly selected patient from each group. 
The study was approved by the Regional Ethics committee North (Lokala 
forskningsetikkomitten Nord), Stockholm, Sweden, (Dnr 98-341).  
3.1.2 Study II and IV 
Study II and IV used the patient population in the TOTAL-AMI (tailoring of treatment in all-
comers with acute myocardial infarction) project, and the Swedish Web-System for 
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Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated 
According to Recommended Therapies (SWEDEHEART) biobank, were consecutive 
patients with an ACS were included between 2008 and 2015. All Swedish hospitals (n=72) 
are participating in the SWEDHEART national registry, and over 90 % of patients that are 
hospitalized for ACS and 100 % of all undergoing coronary interventions are included. Three 
Swedish regions, Lund-Malmö, Stockholm and Uppsala have biobanks linked to the 
SWEDEHEART registry (165). 
In study II, we used patient samples from patients included in Stockholm from start 2008 
until 2015, in a descriptive study of platelet and endothelial microparticle-concentrations in 
patients with various renal function. Flow cytometry was used to measure microparticle-
concentrations in frozen/thawed plasma. Forty-seven patients from the biobank were selected 
for analysis, to represent the three groups; normal renal function, moderate impaired renal 
function (CKD 3), and severely impaired renal function (CKD 5), but not on dialysis. All 
patients were on dual anti-platelet treatment with aspirin and a P2Y12. 
We hypothesized that patients with ACS and CKD have elevated concentrations of platelet- 
and endothelial microparticles, as compared to patients with preserved renal function, 
indicating more activated platelets and endothelial dysfunction.  
Study IV was a prospective cohort study of the first 1 394 consecutive included patients in 
the biobank. We excluded patients on dialysis treatment. Proteomic methods were used to 
quantify 179 proteins, classified in advance by the TOTAL-AMI study group according to 
their main known biological function.  
In this study it was prespecified to study biomarkers classified as being involved in 
hemostasis or endothelial and vascular regulation, see Paper IV, Table 4S (supplement). 
We hypothesized that some of the selected biomarkers would be of distinct prognostic 
importance in the subgroup of ACS patients suffering renal dysfunction, but not in patients 
with preserved renal function, indicating an importance of separate disease mechanisms in 
renal dysfunction. 
The TOTAL-AMI study was approved by the Ethics committee in Stockholm (Dnr: 
2017/759-31) and conducted according to the Declaration of Helsinki. The project and the 
proteomic analyses were supported by the Swedish Foundation for Strategic Research (grant 
no. KF10-0024). 
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3.1.3 Study III 
Study III was a substudy of the SOLID trial (166). This was a double blind randomized 
placebo controlled trial with CKD 3-4 patients, without diabetes mellitus. GFR was estimated 
using the MDRD formula. Patients were randomized to either placebo, 1 µg, or 2 µg 
paricalcitol daily for 12 weeks of treatment. The patients were recruited from the Department 
of Nephrology at Danderyd University Hospital, Stockholm, Sweden. The SOLID study 
showed that vitamin D treatment preserved macrovascular endothelial function assessed by 
FMD, and that it reduced proinflammatory cytokines (64, 167). 
In the present substudy, we hypothesized that the maintained endothelial function and 
reduced inflammatory activation would be reflected in reduced concentrations of subtypes of 
microparticles, measured by flow cytometry. 
All patients provided written informed consent and the study protocol was approved by the 
regional Ethics Committee of Stockholm, Sweden. The trial was registered on 
clinicaltrials.gov (SOLID study; NCT01204528). 
3.2 METHODS 
3.2.1 Global hemostasis 
The assay Fibrin OD sum evaluates the global hemostasis by measuring the summation of 
fibrin optical density using a spectrophotometer. The readings from the spectrophotometer, 
expressed as arbitrary units, reflects the capacity of fibrin formation in a plasma sample, 
under the influence of both coagulation and fibrinolysis, thus independent of the endothelium 
and platelets. By analyzing different parts of the spectrophotometer-signal over time, the 
Coagulation activation profile (Cp), Fibrinolysis activation profile (Fp) and the amount of 
fibrin formed over time, as an indicator of overall hemostatic dynamics, termed Fibrin optical 
density sum (Fibrin OD-sum) can be calculated. 
The procedures of the global assay are described in detail elsewhere (168). In brief, in each 
well of a microtitre-plate, an rt-PA solution is mixed with the plasma sample and a 
coagulation triggering solution is added. A spectrophotometer at the wavelength of 405 nm 
and 24°C, records the optical density (OD) every 30 sec for 300 min creating a fibrin-time. 
The curve reflects the rates of fibrin formation and degradation (fibrinolysis) over time. The 
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software analyses the data along the curve and identify the time to the start of fibrin, the 
maximum rate of formation, the time to maximum rate of fibrin formation, time to detectable 
fibrin degradation, the maximum rate of fibrin degradation, and the time to the maximum rate 
of degradation.  
The parameters obtained from analysis of ∆ODs were put into two formulas that define Cp 
and Fp:  
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The Fibrin OD-sum was determined as the sum of all the absorbance values obtained from 
the 601 readings, using Microsoft Office Excel, where the “blank” value had been subtracted 
from each OD value. 
3.2.2 Microparticles 
Antecubital venous blood was sampled in test tubes containing 1/10 0.129 M sodium citrate. 
Samples were centrifuged within 20 min at 2 000 g for 20 min in room temperature (RT), and 
platelet poor plasma (PPP) collected and frozen in aliquots at -80 °C until analysis.  
PPP was thawed and centrifuged again at 2 000 g for 20 min at RT. The supernatant was then 
centrifuged again at 13 000 g for 2 min. Twenty μl of the supernatant was incubated for 20 
min in dark with lactadherin, and the antibodies. 
Lactadherin was used as a probe to detect phospholipid phosphatidylserine (PS)(113).  
MPs were defined as particles < 1.0 μm in size positive to lactadherin, and platelet 
microparticles PMPs were detected with antibodies against cytokines or proteins exposed on 
the platelet surface, such as integrin glycoprotein GP IIb (CD41), platelet activation markers 
P-selectin (CD62P) and CD40L (CD154).  
Endothelial microparticles EMPs were detected by using antibodies against E-selectin 
(CD62E), intercellular adhesion molecule (ICAM-1, CD54) or vascular cell adhesion 
molecule (VCAM-1, CD106). Leucocyte derived MPs were detected with an antibody 
directed against the pan-leukocyte antigen CD45. 
Flow cytometry counts, sorts and detect cells or particles, suspended in a liquid, by letting 
them pass through a flow chamber, one by one, while laser beams pass them. The size of the 
cells or particles is determined by detecting the light passing, in line with the laser beam: the 
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forward scattering. The light hits the antibodies labelled to the cells or microparticles, and the 
side scattering of the light is detected, each cell with specific fluorochromes enabling the flow 
cytometer to detect several properties of the cell simultaneously. 
The study II, and III used a Beckman Coulter Gallios flow cytometer. The MP-gate was 
determined using Megamix beads (0.5 μm, 0.9 μm and 3.0 μm, BioCytex, Marseille, FR).  
The MP counts are presented as MPs per µl plasma. 
3.2.3 Proteomics 
3.2.3.1 Multiple reaction monitoring assay 
The targeted proteomic analysis by the Mass spectrometry method Multiple reaction 
monitoring (MRM) assay is an analytical technique to determine and quantify proteins. It 
sorts and analyses the peptides/proteins studied according to the mass-to-charge ratio and can 
perform parallel analysis of a large number of proteins in one sample, previously described in 
detail (169, 170). 
A mass spectrometer works in several steps. First, the sample is vaporized and ionized by an 
ion source. The ions are then accelerated. The acceleration and tendency for an ion to move 
straight forward is proportional to its mass. The ions are deflected by electromagnets and the 
force needed to deflect the ion is proportional to its charge. The path the ion takes is 
proportional to its mass-charge ratio. The detected ion sequences are then matched to known 
peptide-sequences, and in turn matched to known proteins (1-3 peptides per protein). In this 
study, 87 proteins were quantified. A triple quadrupole mass spectrometer (TSQ Vantage) 
was used for the MRM assay, with two acceleration steps analyzing the mass-to-charge ratio. 
The Nano spray Flex Ion source, and an EASY n-LC II pump were used. The raw data were 
handled by software Skyline v3.5 (macCoss Lab Software, Seattle, WA, US).  
3.2.3.2 Proximity extension Assay 
Proseek Multiplex OLink CVD-1 chip is based on the technique Proximity Extension Assay 
(PEA), previously described in detail (171, 172). This technique enables analysis of multiple 
biomarkers simultaneously with high specificity. 92 selected proteins all related to 
cardiovascular disease were included in this commercially available analysis kit. Briefly, a 
pair of antibodies targeted to a specific biomarker, each carry a short oligonucleotide/ DNA 
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molecule with weak affinity to each other, PEAprobes. When the antibodies attach to the 
target biomarker, the DNA molecules become in proximity of each other, a DNA polymerase 
extend the oligonucleotides so that a new DNA sequence is formed, specific for every 
biomarker. The DNA sequence can be amplified and quantified by quantitative real time 
PCR, the numbers of PCR templates reflecting the concentration of the biomarker in the 
sample.  
3.2.3.3 Statistical methods 
The two proteomic methods used in this study quantified 179 biomarkers. A priori there were 
36 proteins selected for analysis in this hypothesis-testing study, all considered either 
involved in prothrombotic pathways, anti-thrombotic or profibrinolytic pathways, or related 
to endothelial function or vascular regulation, and listed in Paper IV, Table 4S (supplement).  
First, it was assessed which biomarkers that correlated with renal function. Second, the 
patients were stratified into two groups, eGFR ≥ 60 and eGFR < 60 ml/min/1.73 m2, and 
associations with outcome were estimated using Cox regressions analysis.  
Sample size in studies with multiple markers cannot be based on a traditional power 
calculation. We considered this a high-risk group for recurrent events; they were followed for 
a median of 3 years, so the number of patients included in the study was considered large 
enough to answer the research question in the pre-specified subgroups. 
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4 RESULTS, DISCUSSION AND METHODOLOGICAL 
CONSIDERATIONS 
4.1 STUDY I 
4.1.1 Results and discussion 
In study I, we showed that the hemostasis in patients with CKD was shifted towards a pro-
coagulative state, due to both an increased fibrin formation and an impaired fibrinolytic 
capacity, despite no change in the concentrations of the fibrinolytic inhibitors PAI-1 and 
TAFI. We included 49 patients in the study, 13 controls, 21 patients with CKD 4 and 15 
patients on hemodialysis, see Table 5 and 6.  
 
Table 5. Markers of hemostasis. 
 
Copyright © Wolters Kluwer Health, Inc. All rights reserved. Published by permission from the journal Blood 
Coagulation & Fibrinolysis 2016. 
 
The global assay Fibrin Od sum reflects the capacity of plasma to form fibrin, under the 
influence of both coagulation and fibrinolysis. The fibrinolysis activation profile (Fp) reflects 
the fibrinolytic capacity. 
We found an impaired fibrinolysis (Fp) in patients with severe renal impairment. At the same 
time, we observed low or normal fibrinolytic inhibitors in plasma, i.e. PAI-1 and TAFI, 
indicating that mechanisms other that those involving PAI-1 and TAFI are involved.  
 The fibrin network demonstrated by SEM showed a denser network in patients with severely 
impaired renal function, and fibrinogen concentrations were higher in both patient groups. 
High fibrinogen have been shown to be associated with dense fibrin clots (91). The 
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architecture of the fibrin network and fibrin clot is of importance for the ability to degrade the 
fibrin (173), partly because the involved enzyme plasmin is quite large and needs to enter the 
clot to lyse it. Thus, the denser fibrin network per se hinder plasmin and this might be a 
partial explanation to the impaired fibrinolysis observed.  
It has previously been shown that impaired fibrinolysis assessed by this global method is 
associated with worse outcomes in young patients with myocardial infarction (174), and it 
has been shown in CKD patients that other global methods (Global Thrombosis Test, and 
Fibrin Clot structure) can predict major adverse cardiovascular events (93, 95).  
Patient characteristics in this study are demonstrated in Table 6. Patients were well matched 
regarding age and gender. 
 
 
Table 6. Study population characteristics. 
 
Published by permission from the journal Blood Coagulation & Fibrinolysis 2016. 
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Diabetes mellitus which is an important factor that can influence hemostasis, was however 
more common in the CKD 4 group; 38% vs. 13 % in the hemodialysis group, and none in the 
control group. There were too few cases with respectively without diabetes mellitus in each 
group to be able to perform a formal regression analysis. Instead, we tested between-group 
differences by Kruskal–Wallis test and when only including the diabetes mellitus patients, we 
found the same result for fibrin OD sum between the three groups. When testing the whole 
cohort with Mann-Whitney U test, for differences between diabetes mellitus group and no 
diabetes mellitus, there were no differences regarding Fibrin ODsum, Cp or Fp, but 
fibrinogen was significantly higher in the diabetes groups. It cannot be completely excluded 
that the comorbidities affect our findings, but it seems that diabetes mellitus does not have an 
effect. 
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Figure 4. Box plots of the global assay fibrin OD-sum. 
 
Fibrin OD-sum in arbitrary units that measures the summation of fibrin optical 
density reflecting the capacity of fibrin formation under the influence of both 
coagulation and fibrinolysis. Both CKD groups show increased fibrin formation. 
Values for the thick bar shown in the boxes are median, the box include the lower 
and upper quartile. Whiskers show 90 % and outliers are represented by (*). 
Copyright © 2016 Wolters Kluwer Health, Inc. Pictures published by permission from the 
journal Blood Coagulation & Fibrinolysis 
 
Figure 5. Box plots of fibrinolysis activation profile (Fp). 
 
Fibrinolysis activation profile (Fp) reflecting the fibrinolytic capacity in arbitrary units. 
The hemodialysis group showed an impaired fibrinolysis. Fp in control group vs CKD 
4 non-significant. Values for the thick bar shown are median, the box include the 
lower and upper quartile. Whiskers show 90% and outliers are represented by (*). 
Copyright © 2016 Wolters Kluwer Health, Inc. Pictures published by permission from the 
journal Blood Coagulation & Fibrinolysis  
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Figure 6. Scanning electron microscopy of the fibrin network from a control subject 
(a), a CKD stage 4 patient (b), and a hemodialysis patient (c). The tighter fibrin 
network is illustrated in both kidney disease groups 
  
Copyright © 2016 Wolters Kluwer Health, Inc. Published by permission from the journal Blood Coagulation & Fibrinolysis. 
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4.1.2 Limitations and methodological considerations 
There are several limitations in this study. The study is rather small, and that always adds a 
risk that simply chance affected the result. The comorbidity differed between the three 
groups, and comorbidity may affect the result. Between group differences are possible to 
adjust statistically for in larger samples, but in smaller studies it is difficult. Hemodialysis is 
also a potential confounder when studying hemostasis. The patients are treated with iv 
heparin or low molecular weight heparin right before or during the hemodialysis session, but 
the effect of these drugs administered iv only stays up to 4-6 hour. To minimize this potential 
effect, the samples for the study were taken right before a dialysis session after the 2-3 day 
long interdialytic period. 
The method of studying the overall hemostasis with a functional assay, to evaluate 
coagulation and fibrinolysis, has obvious advantages compared with studying single 
parameters, but it does not include influential effects of platelets and dysfunctional vascular 
endothelial cells that may contribute to the pathology. 
4.2 STUDY II  
4.2.1 Results and discussion 
In study II, we showed that among patients with ACS, patients with impaired renal function 
had increased concentrations of PMPs, and also of PMPs expressing platelet activation 
markers CD40L (CD154) and P-selectin (CD62P). CKD patients also had elevated 
concentration of EMPs expressing markers of endothelial activation E-selectin (CD62E), 
Table 5. These results indicate higher platelet activation in CKD patients, despite concurrent 
dual antiplatelet treatment, and further impaired endothelial function despite statin treatment. 
There were 47 patients included in the study, all with ACS, 19 with preserved renal function, 
15 with CKD 3, and 13 with CKD 4-5.  
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Table 7. MP concentrations. 
 
Normal kidney 
function (H) 
n=19 
CKD 3 
N=15 
CKD 4-5 
N=13 p-valuea 
PMP(CD41) 
count/µL 
424 (328-534) 600 (401-888) 1576 (666-2351) 
0.001a 
(CKD3 vs CKD 4-5, p=0.022)b 
(CKD3 vs H, p=0.186) b 
(CKD4-5 vs H, p=0.002) b 
P-selectin 
positive PMP 
(CD 62P) 
count/µL 
106 (79-158) 
147  
(111-174) 
253 (227-461) 
<0.001a 
(CKD3 vs CKD 4-5, p<0.000)b 
(CKD3 vs H, p=0.106) b 
(CKD4-5 vs H, p<0.000) b 
CD40L positive 
PMP (CD154) 
count/µL 
101 (71-134) 142 (125-187) 210 (174-237) 
<0.001a 
(CKD3 vs CKD 4-5, p<0.003)b 
(CKD3 vs H, p=0.006) b 
(CKD4-5 vs H, p<0.000)b 
E-selectin 
positive MP 
(CD 62E) 
count/µL 
83 (53-140) 197 (120-245) 245 (189-308) 
<0.001a 
(CKD3 vs CKD 4-5, p<0.118) b 
(CKD3 vs H, p=0.002) b 
(CKD4-5 vs H, p<0.000)b 
Values expressed as median and interquartile range. a = p value for 
comparison between the three groups. b = p value for comparison between 
the two groups listed. Published by permission from BMC Nephrology 2019. 
 
Comparisons between PMP concentrations between the three groups are demonstrated in 
Figures 5-7. Most previous studies reports that both ACS patients (138), and CKD patients 
(136), have increased concentrations of PMPs compared with controls. A recent study 
demonstrated that CD62P+ PMPs predicted increased risk of a new cardiovascular 
event(139). However, there are conflicting data, as a study from 2014 showed that CD41 
PMPs were not elevated in ACS patients compared with controls, and could not predict 
outcome (140). In study I, the concentration of MPs expressing the platelet activation marker 
P-selectin were elevated in patients with severe CKD, but not in moderate CKD. In a 
previous study, it was found that platelet reactivity was altered only in patients with moderate 
renal impairment, not in mild renal impairment, and the authors discussed a possible 
threshold where renal impairment starts inducing platelet activation (175).  
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Figure 7. Boxplot of PMPs (CD41) in the tree groups. 
 
 
Figure 8. Boxplot of P-selectin (CD62P) positive PMPs.  
 
 
Figure 9. Boxplot of CD40L (CD154) positive PMPs.  
All published by permission from BMC Nephrology 2019. 
EMPs expressing the endothelial activation marker E-selectin CD62E were elevated in both 
CKD groups, with increasing concentrations as the renal function declined. EMPs have been 
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shown to be elevated in CKD (136), and that CD31+ EMPs is associated with outcome in 
ESRD patients (126). The results from study II indicates a more pronounced endothelial 
dysfunction in CKD patients. Further studies are needed to provide information on whether 
EMPs are a valuable surrogate marker in ACS patients, and if so, which endothelial antigen is 
best to use. 
There were more diabetes mellitus patients in the CKD groups. We performed a regression 
analysis including diabetes mellitus, but found no differences in correlation with MPs and 
renal function with and without diabetes mellitus. 
 
 
Figure 10. Boxplot of E-selectin positive EMPs count/µL in the tree groups. 
Published by permission from BMC Nephrology2019. 
4.2.2 Limitations and methodological considerations 
Major limitations are the small number of patients included, with differences between the 
groups regarding co-morbidity, which we tried to assess by performing a regression analysis. 
To determine renal function and diagnose patients with CKD is not possible based on just one 
value of creatinine and without data regarding albuminuria, since the diagnose CKD require 
at least 3 months stable renal function loss. This is the same problem in many studies where 
renal function is studied in an acute setting. In the present study, we adjudicated all patient’s 
electronic medical records and could determine that the eGFR level at admission reflected a 
true chronic state. Another limitation is that samples were collected 1-3 days after admission 
due to the ACS, and that might affect the concentrations of the MPs. It would have been 
desirable to collect the samples the same day for every patient included in the study. A 
methodological limitation may be that the freezing procedure of the sample could produce 
cell membrane fragments disturbing the analysis. A study of the flow cytometry method of 
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detecting MPs has been performed in our laboratory, and showed low presence of cell 
fragments after the same sample handling that was used in our study (176). 
4.3 STUDY III  
4.3.1 Results and discussion 
Study III was a substudy of the SOLID trial (166), were 2 µg daily paricalcitol treatment 
demonstrated preserved macrovascular function, assessed by FMD, after 12 weeks treatment, 
in patients with CKD stages 3-4 without diabetes mellitus. 
The aim of this study was to assess if paricalcitol treatment affected concentrations of 
endothelial microparticles expressing the proatherosclerotic markers ICAM-1 and VCAM-1. 
There were 36 patients included in the study, divided into three treatment groups, 1 µg, 2 µg 
or placebo. The groups had similar eGFR and stage of CKD and baseline measurements of 
vascular function (FMD and pulse wave velocity) were well matched (Table 8, Figure 11) 
(64). Age was statistically different at baseline, the patients in the placebo group were slightly 
older. There were no statistical differences regarding medication and previous CVD, however 
there was a difference in absolute numbers with less previous CVD in the 2 µg group.  
Paricalcitol treatment in CKD patients did reduce the concentrations of ICAM-1+ MPs, 
indicating a less proatherosclerotic endothelium. Furthermore, concentrations of EMPs, 
PMPs and leukocyte derived MPs (LMPs) induced by cell-activation were maintained, which 
might be signs of a more preserved and reactive endothelium. 
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Table 8. Baseline characteristics in the SOLID trial.  
 
 
 
Figure 11. Maximum increase in brachial artery diameter in percentage from baseline 
by FMD, before and after 3 months treatment with paricalcitol or placebo. © 2015 S. 
Karger AG, Basel. Published by permission of American J Nephrology 2015. 
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Baseline plasma levels before treatment of 25OH-vitamin D, calcium, phosphate or levels of 
parathyroid hormone (PTH) did not differ between the groups (Table 9). Data post-treatment 
showed an expected PTH suppression, but no statistically significant increase in calcium 
levels or other routine laboratory markers. 
 
Table 9. Clinical characteristics and laboratory markers before and after the intervention. 
 
BP: blood pressure, eGFR: estimated glomerular filtration rate, Ualb/crea: urine albumin creatinine ratio, PTH: 
parathyroid hormone. Values are expressed as mean (SD). P-value for interaction of treatment and time. 
 
Table 10. MP concentrations before and after the intervention. 
 
ICAM-1: intercellular adhesion molecule-1, VCAM-1: vascular adhesion molecule -1, CD62E+: endothelial 
MPs, CD45+: Leukocyte MPs, CD41+: platelet MPs, CD41+62p+: platelet MPs, CD41+154+: platelet MPs. 
Values are expressed as mean (SD).  
 
Before treatment there were no significant differences regarding the ICAM-1+ and VCAM-
1+ MP concentrations in the three groups (Table 10). 
The concentrations of ICAM-1+ MPs showed a significant decline in the treatment groups, 
assessed by repeated measures ANOVA (p=0.04), and increased in the placebo group. 
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VCAM-1+ MPs did not change significantly during the study period. The concentrations of 
MPs with origin from activated endothelial cells, platelets and leucocytes remained 
unchanged in the treatment group of 2 µg and declined in the placebo and 1 µg group. The 
CD62E+ EMPs decreased in the placebo group.  
The SOLID trial demonstrated that three months treatment with 2 µg paricalcitol preserved 
endothelial function and reduced inflammatory cytokines. Soluble ICAM-1 is known to 
reflect inflammation and can predict mortality in CKD patients (177). The result of reduced 
ICAM-1+ MPs goes in line with these previous findings that can be interpreted as a potential 
protective effect of paricalcitol. 
When evaluating the significance of MPs in disease it is important to be aware of the MP 
subtype. Jimenez et al. demonstrated in vitro that CD31+ EMPs where induced by apoptosis, 
and CD62E induced by activation (178). There are in vitro studies on endothelial cell lines 
demonstrating lower concentrations of EMPs after vitamin D treatment, interpreted as a 
protective effect against apoptosis (179, 180), but there are no in vivo studies. There are 
several studied indicating that high concentrations of CD31+ and CD144+ EMPs and also 
CD62E+ EMPs are related to endothelial dysfunction (127, 181-187). A recent study by 
Sansone et al. on hypertension and EMPs, demonstrated CD144+ EMPs and CD62E+ EMPs 
more related to mechanical injury and activation, and CD31+ more responsive of chronic 
changes (188). 
There are not many studies on clinical interventions and EMPs. A study on atorvastatin 
treatment in non-CKD patients demonstrated a rise in CD144+ EMPs following treatment 
(189, 190), and the authors interpreted that the rise of EMPs were a sign of a more reactive 
and healthy endothelium. In another study, Almquist et.al. demonstrated that statin treatment 
vs. placebo caused elevated concentrations of CD144+ EMPs, in CKD patients with diabetes 
mellitus. In that study, the concentrations of CD62E+ EMPs were higher at baseline in the 
CKD group, compared to the non-CKD group, all with diabetes. Only the non-CKD groups 
increased their concentration of CD62E+ EMPs on statin treatment (123). Since several 
studies have demonstrated beneficial effects of statin treatment, the rise of the CD62E+EMPs 
may be interpreted as a possible beneficial effect. 
The SOLID trial demonstrated protective effects on the endothelium, and reduced levels of 
proinflammatory cytokines by paricalcitol treatment. This was further demonstrated in this 
substudy as a decline in ICAM-1+ EMPs. We speculate these findings of MPs to reflect a 
preserved endothelial cell function. However, in the field of MPs, further research is 
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necessary to better understand what subpopulations of MPs that are important in which 
disease, and what a change in concentrations implicates. 
4.3.2 Limitations and methodological considerations 
There are several limitations in this study. The study is relatively small in number of patients 
and with a short follow up, which limits the generalizability of the results. The differences in 
age between the groups despite the randomization is unfortunate, but may happen by chance 
in small studies, and is not considered to have a major influence on the results in the present 
study, as the RCT remains the best available methodology for causal inference. 
4.4 STUDY IV 
4.4.1 Results and discussion 
In study IV, 36 biomarkers, all associated with hemostasis, vascular and endothelial function 
were evaluated in a prospective cohort study of 1 370 ACS patients. First, it was assessed if 
the biomarkers correlated with renal function. Second, the patients were stratified into two 
groups, eGFR ≥ 60 and eGFR < 60 ml/min/1.73 m2, and associations with outcome were 
estimated using Cox regressions analysis.  
There were 1 393 patients included, and after excluding patients on dialysis and patients 
without data on eGFR, 1 370 patients remained for the statistical evaluation. The cause of the 
impaired renal function was not available. The patients with impaired renal function were 
older, had more comorbidities, and more on-going medical treatments. Baseline data of the 
cohort demonstrated in Table 11.  
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Table 11. Baseline characteristics of study population 
  
eGFR < 60  
(n=234) 
eGFR  60  
(n=1 136) 
All  
(n=1 370) 
Age, year 74 (9) 63 (10) 65 (11) 
Female sex 30 % 22 % 24 % 
Current smokers 16 % 29 % 27 % 
Hypertension 78 % 45 % 51 % 
Claudication 10 % 2 % 4 % 
Diabetes 34 % 21 % 23 % 
Heart failure admission a 24 % 5 % 9 % 
Atrial Fibrillation admission a 25 % 7 % 10 % 
History of IHD  36 % 16 % 19 % 
Previous Stroke  15 % 4 % 6 % 
Previous CVD  43 % 18 % 22 % 
Medications and lab values at admission     
Single platelet treatment 62 % 29 % 34 % 
DAPT b 10 % 4 % 5 % 
Oral anticoagulation c 10 % 3 % 4 % 
ACEi/ARB  54 % 27 % 32 % 
Statin 48 % 27 % 30 % 
eGFR mL/min 45.4 (11.9) 87.1 (13.3) 80.0 (20.6) 
Haemoglobin g/l 135 (18) 143 (15) 142 (16) 
Cholesterol mmol/l 4.6 (1.4) 5.1 (1.2) 5.0 (1.3) 
LDL mmol/l 2.8 (1.3) 3.2 (1.1) 3.1 (1.1) 
HDL mmol/l 1.1 (0.4) 1.2 (0.4) 1.2 (0.4) 
Triglycerides mmol/l 1.6 (1.0) 1.7 (1.0) 1.7 (1.0) 
Urate µmol/l 427 (110) 339 (80) 360 (96) 
Albumin g/l 32 (5) 35 (5) 34 (5) 
Calcium mmol/l 2.2 (0.1) 2.3 (0.5) 2.2 (0.5) 
Phosphate mmol/l 1.1 (0.2) 1.0 (0.2) 1.1 (0.2) 
Diagnoses and medications at discharge   
STEMI  38 % 50 % 48 % 
Coronary angiography 87 % 97 % 95 % 
PCI 69 % 83 % 81 % 
Heart failure at discharge d 46 % 32 % 35 % 
Atrial fibrillation discharge d 28 % 9 % 12 % 
Aspirin 91 % 98 % 96 % 
DAPT b 76 % 88 % 86 % 
Oral anticoagulants c 20 % 8 % 10 % 
Antithrombotic combination 
therapy f 
8 % 6 % 6 % 
ACEi/ARB 84 % 83 % 83 % 
Statin 92 % 96 % 95 % 
a  known diagnosis before admission for the index ACS, b Dual anti platelet treatment 
(DAPT), c Vitamin K antagonist treatment, d Diagnosis and medication at discharge from the 
index ACS, f DAPT and Oral anticoagulation 
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In total 18 of the 36 biomarkers correlated with renal function, after adjusting for eGFR, age, 
sex, smoking habits, diabetes, previous CVD and heart failure diagnose at discharge. Out of 
these 18, there were 7 that correlated with eGFR with r² > 0.05, and were included in the 
statistical analysis: TF, protease activated receptor (PAR-1), soluble urokinase plasminogen 
activator receptor (suPAR), thrombomodulin, adrenomedullin, renin, angiotensinogen (Figure 
12). vWf, fibrinogen gamma, alfa and beta chains, and coagulation factors IX, XI and factor 
XIII B-subunit, beta-2-glycoprotein 1, plasma protease C1 inhibitor, vitamin K-dependent 
protein S, and tetranectin correlated with renal function but with r2 < 0.05.  
The analysis of biomarkers in the study indicated an overall prothrombotic state without a 
rise in fibrinolysis activation, in patients with reduced renal function. TF had a strong 
correlation with renal function. In previous studies, TF demonstrated a correlation with both 
CKD and CVD (191-193), and the same was found in the present study where TF could 
predict the composite outcome of MI, HF, stroke or death in the group of patients with 
impaired renal function. There were several biomarkers that correlated inversely with renal 
function: vWf, fibrinogen alpha, beta and gamma chains, coagulation factors IX, XI and 
factor XIII B-subunit, fibrinogen gamma, alfa and beta chains, factor XI, all indicating a 
prothrombotic state in CKD.  
PAR-1 increased as renal function declined but was not associated with outcome. This 
finding might indicate a state of more activated platelet, in ACS patients with CKD. On the 
other hand, we did not find elevated soluble CD40L in the CKD patients, which in in contrast 
to previous finding (74, 194). This may perhaps, be explained by the intense antiplatelet 
therapy used in ACS patients.  
The fibrinolytic system counteracts the coagulation system and is activated in response to the 
coagulation process. In the state of an activated coagulation system in ACS patients and 
further activated among those with CKD, we did however, not find signs of increased 
fibrinolytic activity. There were no elevations in endogenous plasminogen activator tPA. 
Tetranectin, that increases fibrinolytic activity, was decreased. Plasminogen was not 
increased. This was together interpreted as signs of attenuated fibrinolysis.  
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Figure 12. The 7 biomarkers that correlated significantly with eGFR with a coefficient of determination 
      (r2) > 0.05. 
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UPAR is expressed by a variety of cells and is an important plasminogen activator when it 
ligates to urokinase plasminogen activator (uPA). In the soluble circulating form suPAR has 
less profibrinolytic properties (195), and is involved in a variety of biological processes, 
including immune modulating and fibrosis (196, 197) and can predict both a decline in renal 
function and predict incidence of heart failure and cardiovascular death (198, 199). SuPAR 
correlated with renal function in this present study. Other studies have showed that the 
uPA/suPAR system correlates with uremic toxins accumulated as renal function decline, but 
that this correlation only is present in mild, not severe renal impairment (200). Thus, suPAR 
can be affected of the degree of renal impairment and exert different functions in different 
stages if CKD. This could be an explanation why suPAR predicted heart failure only in the 
renal group. 
Thrombomodulin has important anticoagulant and vascular protective properties, and soluble 
thrombomodulin is considered a marker of endothelial dysfunction (201, 202). It has a 
complex role where increasing concentrations is considered anticoagulative in healthy 
individuals, and simultaneously is associated with severity of disease in patients with CVD 
(54). There is conflicting data regarding outcome related to thrombomodulin. There are 
reports of increased risk of CVD with high concentrations as well as with low (90, 203-205).  
In our data set, thrombomodulin increased as renal function declined, and was associated with 
reduced risk of heart failure in the ACS patients with impaired renal function. The Cox 
regressions in our analysis were adjusted for age, sex, diabetes mellitus, previous CVD and 
heart failure. This is a novel finding and warrant further studies.  
Adrenomedullin concentrations increased as renal function declined. Adrenomedullin release 
is regarded as a compensatory response to organ damage, and have positive effects on the 
endothelium (206).  In line with other studies (207), our finding was that adrenomedullin was 
associated with increased risk of death and heart failure, but only in the group with preserved 
renal function. In the group with impaired renal function it did not predict any outcome. One 
interpretation of this may be that when the endothelial dysfunction aggravates as renal 
function decline, other disturbances become relatively more important, and adrenomedullin 
loses its predictive value. 
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Renin and angiotensinogen correlated with renal function as eGFR declined. Renin was 
associated with bleeding in the normal renal function group, and angiotensinogen with death 
in the reduced renal function group. The importance of the renin-angiotensin-aldosterone 
system (RAAS) for cardiovascular outcome is well recognized (208, 209). The substrate of 
all angiotensin peptides is angiotensinogen, and intra-renal angiotensinogen concentrations 
have been linked to hypertension and cardiovascular disease (210). However, the RAAS 
system, and the constituents involved such as renin and angiotensinogen, is affected of 
treatment with RAAS inhibitors, which was more common in the group with impaired renal 
function (54 % vs. 27 %). This association may be biased due to differences in medication in 
the groups. 
In summary, the correlations indicated a prothrombotic state, without a simultaneous 
activation of the fibrinolytic system, in patients with reduced renal function. Our data are in 
line with our hypothesis that biomarkers associated with hemostasis, vascular and endothelial 
function could predict outcome among patients with impaired renal function.  
Our main conclusion is that the predictive value of biomarkers differed in renal patients, so in 
the field of biomarkers, it might therefore not be sufficient to adjust for renal function, rather, 
we speculate that renal failure could be regarded as a separate disease state with its own 
distinct pathophysiology. 
There were additional interesting findings of thrombomodulin as having a potential protective 
role among CKD patients with ACS, and the increase in suPAR noticed, potentially involved 
in pathophysiology of heart failure.  
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Table 12  Cox Models of HRs with 95% confidence intervals of biomarkers for predicting outcome 
in ACS patients stratified by renal function group. 
  
eGFR < 60 (n=234) 
 
eGFR ≥ 60  (n=1136) 
  HR(95%CI) p-
value 
 HR(95%CI) p-value 
Death n=45   n=50   
First step TF 3.55 (0.85-14.76) 0.082 TF 2.95 (1.01-8.68) 0.049 
 PAR-1* 0.48 (0.15-1.55) 0.221 PAR-1 0.82 (0.35-1.91) 0.648 
 suPAR** 1.16 (0.19-7.01) 0.873 suPAR 0.85 (0.21-3.35) 0.813 
 Thrombomodulin 0.53 (0.16-1.77) 0.305 Thrombomodulin 0.89 (0.31-2.61) 0.835 
 Adrenomedullin 0.99 (0.36-2.74) 0.987 Adrenomedullin 2.47 (1.02-5.93) 0.044 
 Renin 1.10 (0.74-1.64) 0.643 Renin 0.95 (0.69-1.32) 0.779 
 Angiotensinogen*
** 
2.61 (0.95-7.19) 0.063 Angiotensinogen 2.15 (0.88-5.25) 0.093 
             
Last step Angiotensinogen 2.91 (1.04-8.13) 0.042 Adrenomedullin 2.50 (1.26-4.97) 0.009 
       Angiotensinogen 2.17 (0.93-5.06) 0.072 
MI n=32   n=90   
First step TF 2.10 (0.48-9.21) 0.325 TF 1.03 (0.47-2.23) 0.950 
 PAR-1 1.28 (0.34-4.79) 0.714 PAR-1 1.06 (0.60-1.87) 0.837 
 suPAR 1.47 (0.18-12.07) 0.717 suPAR 2.37 (0.89-6.31) 0.084 
 Thrombomodulin 0.27 (0.06-1.21) 0.087 Thrombomodulin 0.75 (0.33-1.69) 0.491 
 Adrenomedullin 0.76 (0.27-2.13) 0.602 Adrenomedullin 0.81 (0.45-1.47) 0.484 
 Renin 0.80 (0.51-1.26) 0.332 Renin 1.03 (0.80-1.33) 0.823 
 Angiotensinogen 0.50 (0.14-1.74) 0.274 Angiotensinogen 0.79 (0.40-1.55) 0.489 
             
Last step       suPAR 2.07(1.09-3.96) 0.027 
Ischemic 
stroke 
n=8   n=23   
First step TF ****   TF 0.99 (0.20-4.93) 0.991 
 PAR-1     PAR-1 1.22 (0.37-4.08) 0.746 
 suPAR     suPAR 2.06 (0.28-15) 0.480 
 Thrombomodulin     Thrombomodulin 0.38 (0.07-1.97) 0.249 
 Adrenomedullin     Adrenomedullin 1.22 (0.35-4.26) 0.759 
 Renin     Renin 1.00 (0.61-1.63) 0.998 
 Angiotensinogen     Angiotensinogen 3.93 (1.02-15) 0.046 
             
       Angiotensinogen 3.10 (0.85-11) 0.086 
Bleeding n=7   n=18   
First step TF ****   TF 3.10 (0.55-18) 0.202 
 PAR-1     PAR-1 1.26 (0.32-4.96) 0.746 
 suPAR     suPAR 2.05 (0.18-23) 0.559 
 Thrombomodulin     Thrombomodulin 1.75 (0.26-12) 0.567 
 Adrenomedullin     Adrenomedullin 0.29 (0.08-1.15) 0.078 
 Renin     Renin 2.36 (1.30-4.31) 0.005 
 Angiotensinogen     Angiotensinogen 0.71 (0.16-3.04) 0.642 
             
Last step       TF 3.61 (0.89-15) 0.073 
       Renin 2.09 (1.19-3.66) 0.010 
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  HR(95%CI) p-
value 
 HR(95%CI) p-value 
HF n=27   n=47   
First step TF 1.68 (0.35-8.15) 0.520 TF 1.16 (0.38-3.52) 0.796 
 PAR-1 0.86 (0.22-3.36) 0.823 PAR-1 0.75 (0.35-1.60) 0.449 
 suPAR 7.15 (0.68-75.54) 0.102 suPAR 0.94 (0.23-3.88) 0.929 
 Thrombomodulin 0.26 (0.06-1.08) 0.064 Thrombomodulin 0.65 (0.22-1.95) 0.441 
 Adrenomedullin 0.98 (0.26-3.77) 0.979 Adrenomedullin 6.72 (2.67-17) 0.000 
 Renin 1.03 (0.65-1.63) 0.912 Renin 1.24 (0.87-1.79) 0.235 
 Angiotensinogen 1.22 (0.32-4.64) 0.771 Angiotensinogen 0.60 (0.22-1.61) 0.313 
             
Last step suPAR 10.54 (1.99-
55.86) 
0.006 Adrenomedullin 5.15(2.67-9.93) 0.000 
 Thrombomodulin 0.25 (0.08-0.81) 0.021       
Composite n=68 a   n=165a   
First step TF 1.93 (0.70-5.38) 0.207 TF 1.21 (0.67-2.17) 0.529 
 PAR-1 0.85 (0.35-2.06) 0.726 PAR-1 0.94 (0.62-1.44) 0.786 
 suPAR 1.38 (0.34-5.55) 0.648 suPAR 1.81 (0.88-3.73) 0.110 
 Thrombomodulin 0.43 (0.17-1.10) 0.078 Thrombomodulin 0.56 (0.31-1.02) 0.060 
 Adrenomedullin 0.95 (0.46-2.07) 0.952 Adrenomedullin 1.83 (1.16-2.91) 0.010 
 Renin 0.95 (0.70-1.29) 0.736 Renin 1.09 (0.90-1.31) 0.383 
 Angiotensinogen 1.88 (0.85-4.14) 0.120 Angiotensinogen 1.07 (0.64-1.78) 0.799 
           
Last step TF 2.53 (1.04-6.16) 0.040 suPAR 2.22 (1.15-4.29) 0.017 
 Thrombomodulin 0.47 (0.20-1.09) 0.077 Thrombomodullin 0.58(0.34-0.96) 0.036 
    Adrenomedullin 2.00(1.28-3.10) 0.002 
Hazard Ratios for the biomarkers n=7 related to eGFR with a coefficient of determination (r2) above 0.05.  
Cox Regression performed by Backword selection procedure. First and last step reported in this table. HRs Adjusted for 
eGFR, age, sex, smoking habits, diabetes, previous CVD and heart failure diagnose at discharge.  
Composite outcome of MI, HF, stroke or death. Myocardial infarction (MI). Heart failure (HF). * Proteinase activated 
receptor 1 (PAR-1). **Urokinase plasminogen activator surface receptor (suPAR). ***Angiotensinogen: value transformed 
to natural logarithmic scale. **** Too few events to perform an analysis. 
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4.4.2 Limitations and methodological considerations 
There are several potential limitations with the present study. First, the study population was 
relatively younger and healthier compared to an unselected ACS population. There were 
more STEMI and more PCIs performed, as well as fewer patients with CKD. This is a 
common observed selection bias in studies like this, and something to consider when 
interpreting data and applying results on the general ACS population. Second, this was a 
hypothesis testing study and corrections for multiple testing was not performed. Third, there 
were too few events of bleeding and stroke in the group with impaired renal function.  
Fourth, all markers selected were based on those that were available through the PEA/MRM 
methods, while several markers of known prognostic importance were absent. Fifth, data on 
concentrations need to be verified, with more established quantitative methods. Fifth data on 
some important risk factors were missing, due to lack of reliable data at the time of inclusion, 
so adjustments for some known risk factors such as blood pressure levels, was not possible. 
Last, the proteomic methods analyze semi-quantitative concentrations of biomarkers. 
Consequently, results regarding individual marker concentrations need to be verified, with 
more established quantitative methods.  
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5 GENERAL DISCUSSION AND METODOLOGICAL 
CONSIDERATIONS 
The key findings of this study were that: 
 CKD is a prothrombotic state, with impaired fibrinolysis, activated platelets and a dense 
fibrin network.   
 Patients with ACS and renal dysfunction have higher concentrations of microparticles 
indicating platelet activation and endothelial dysfunction. 
 Paricalcitol treatment in patients with CKD affect concentrations of endothelial 
microparticles expressing surface markers that may indicate a protective effect. 
 In patients with ACS and renal dysfunction, several biomarkers indicate a prothrombotic 
state. 
 Biomarkers associated with hemostasis, vascular regulation and endothelial function are 
associated with long-term outcome among patients with impaired renal function.  
 
There are several strengths and limitations with the current study designs and populations 
investigated. Study I was cross sectional, with a control group. There is always a risk of 
selection bias both for the patients included as for the controls. In study II, the patients came 
from a larger cohort, based on a set of criteria, consecutive but not random, which might have 
induced some bias. Study IV was performed on consecutive patients included in a large 
cohort, including three centers in Sweden, which adds strengths and external validity to the 
result. Study III, the randomized trial, has the highest evidence grade, as the randomization is 
performed in order to eliminate systematic errors. Although in smaller randomized trials, 
there can be differences between groups in baseline data, as practical issues and cost limit the 
study size.  
The methods used in the studies have several strengths but also limitations, as discussed in 
the respective chapters. MP analysis with flow cytometry is an extremely sensitive method, 
but also complicated to perform and to analyze. It is a strength that there is a published study 
regarding method reproducibility from our laboratory (176). The global hemostasis assays 
have also been developed and refined in our research group, and used in several publications 
(168, 174, 211). The proteomic methods are developed within the research groups involved in 
the TOTAL-AMI (tailoring of treatment in all-comers with acute myocardial infarction) 
project, and there are several publications using the methods (170, 171). 
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Current drug treatments to reduce thromboembolic events includes platelet inhibition and 
anticoagulants, whereas these results indicate that attempts to restore fibrinolysis or normalize 
fibrin cross-linking may be of clinical importance. There are currently no drugs available to 
restore fibrinolysis in clinical use. However, a recent study demonstrated that valproic acid 
could increase concentrations of the endogenous fibrinolysis activator tPA in mice, and 
through this diminish thrombus formation (212). 
PMPs and EMPs concentrations were elevated in patients with CKD, as reported in Study I. 
Data regarding the role of MPs in ACS and CKD are not consistent. PMPs are even 
considered more procoagulant than platelets. This is due to their ability to carry TF, where 
PMPs are the main source of circulating TF (191), and to their ability to bind factor Va, factor 
VIII and that they can express phosphatidylserine on their surface (112). PMPs also have the 
ability to enhance thrombus formation and deposition of fibrin on atherosclerotic vessels, and 
decrease clotting time, as assessed by thromboelastography (134). These effects could explain 
the poorer outcome associated with increased concentrations of PMPs (139, 140, 213).  
Most studies of PMPs procoagulant properties are performed on non-CKD patients. In one 
study, it was shown that patients with CKD had elevated PMPs compared with controls 
(125). However, these MPs had less procoagulant capacity when transferred into non-uremic 
plasma samples (125). Thus, it is not only the concentrations of MPs that are important but 
also their functional capacity. The platelet dysfunction noticed in patients with CKD probably 
translate to dysfunctional PMPs. Another study assessed MPs from patients with CKD and 
compared these with subjects with normal renal function, and noted that when the MPs were 
removed from the plasma samples, the increased thrombin generation normalized, and 
suggested that MPs are a major cause of the hypercoagulability noticed in patients with CKD 
(114). On the other hand, one study showed that increased concentrations of CD42+PMPs 
correlated to increased risk of bleeding in patients with non-STEMI and normal renal 
function (111).  
In the same study, the MP concentrations correlated inversely with concentrations of the 
fibrinolysis activators tPA and uPA, i.e. higher MPs related to less profibrinolytic markers 
(111).  Taken together, these reports regarding PMP concentrations are difficult to interpret. It 
appears that they have different effects depending on the clinical context. The findings of 
PMPs correlating to bleeding in patients with normal renal function, would certainly be of 
value to investigate further for a putative role in CKD-associated bleeding. 
Proteomic approaches have several limitations. The methods used to quantify the protein 
concentrations cannot directly be translated to concentrations by conventional methods, and 
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confirmatory analyses are often required. The large number of proteins analyzed also makes 
the statistical analysis difficult, with risk for mass-significance. The current approach to test a 
pre-specified hypothesis reduces some of these issues. Our main conclusion is that the 
predictive value of biomarkers differed in renal patients, which appears safe to conclude 
despite these limitations.  
It appears that CKD have several unique pathophysiological characteristics, and may even be 
considered a separate disease state once developed (214). The similar concept of “multiple 
states” is commonly used in clinical practice, for instance primary vs. secondary prevention, 
i.e. the states before or after a CV event.  
One example of how three chronic diseases may develop and co-exist, has recently been used 
by Siriwardhana et al. to explain the progression from CKD, CVD and diabetes mellitus to 
the endpoint of death (Fig 13)(215). 
 
Figure 13. Illustration of distinct chronic disease states and outcomes. Based on a 
thee chronic condition multistate model by Siriwardhana et al. 
 
Thus, it might not be sufficient to adjust for renal function, rather we argue that renal failure, 
once developed, could be regarded as a separate disease state with its own distinct 
pathophysiology. Certainly, the etiology of the CKD is of great importance, but once 
developed, the “non-Framingham” factors induced by CKD would come into play. 
  
CKD CKD-CVD
CVD CKD-DM CKD-CVD-DM DEATH
DM DM-CVD
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6 CONCLUSIONS  
Patients with CKD have hemostatic disturbances demonstrating a procoagulant state, in part 
due to an impaired fibrinolytic capacity and an increased fibrin formation, as well as a tighter 
fibrin network, despite normal concentrations of endogenous fibrinolysis inhibitors 
Patients with ACS and CKD have increased concentrations of PMPs and EMPs indicating 
more activated platelets and endothelial dysfunction, compared to patients without CKD, 
despite concurrent dual antiplatelet and statin treatment.  
Paricalcitol treatment in CKD patients reduces the concentrations of ICAM-1 positive EMPs, 
indicating a less proatherosclerotic endothelium. Concentrations of cell-activation induced 
EMPs, PMPs, and LMPs were maintained, which may be signs of a more preserved and 
reactive endothelium. EMPs might be useful to evaluate endothelial activation, function, or 
damage, but further studies are needed to understand the complex physiology. 
Several biomarkers related to hemostasis, endothelial and vascular function correlate with 
renal function in ACS patients, indicating a procoagulative state, increased platelet activation 
and increased endothelial activation. Some of these were associated with long-term outcome, 
but only in patients with reduced renal function. Thus, it might not be sufficient to only adjust 
for renal function when using biomarkers to predict outcome. Rather, once developed, renal 
failure might be considered a separate disease state with its own distinct pathophysiology  
7 FUTURE PERSPECTIVE 
The pathophysiology of how CKD interact with hemostasis, platelets, endothelium and 
calcium-phosphate metabolism in CVD is indeed complex. The spectrum of mechanisms 
involved concerns all levels, from microRNA to cells, to vessels and organs, causing the 
clinical phenotype with CKD and evident CVD. This PhD project have demonstrated some of 
these mechanisms, hopefully contributing to a better understanding of these. 
There have been many large randomized trials performed on CVD prevention with for 
instance lipid lowering and antithrombotic treatments, involving thousands of patients. These 
trials were not designed to study patients with CKD, and often excluded more advanced 
CKD. Thus, regarding antiplatelet therapy, the current recommendations are largely based on 
result extrapolated after subgroups analyses (216). Regarding vitamin D treatment, there have 
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been no randomized trials with CVD as endpoint in patients with CKD. Since CKD is 
common, and carry a poor prognosis, there is obviously a need for sufficiently powered 
randomized trials in patients with CKD using hard, cardiovascular endpoints. Trials are 
needed to demonstrate safety and efficacy of new antiplatelet therapies, and of vitamin D 
treatment. Until then, contributions to increase the knowledge on specific disease 
mechanisms and surrogate markers in patients with CKD, are valuable. Studies on 
microparticles represent a promising field, both for risk prediction and for evaluating 
treatment effect.  
Our results from the global hemostatic assay indicate that restoring fibrinolysis and 
normalizing fibrin network structure may be a new field in CKD. Currently there are no 
treatments known to achieve this in man, but it may be worth to study the effects of currently 
available drugs, in the right doses, and the right combinations.  
The novel field of gut microbiota is most certainly an interesting future perspective, worth to 
study as a potential risk factor for CKD and CVD.   
Microparticles, flow cytometry investigations and proteomics are important high-technology 
areas that contribute to our increased understanding. However other very important areas in 
current and future clinical nephrology concerns how we can improve patient education and 
patient involvement. How can we help patients to adhere to prescribed medication and 
improve on life style associated risk factors? A better understanding of the 
pathophysiological mechanisms involved and potential treatment effects achieved, may 
enable clinicians to better explain the importance of all these medications, and empower the 
patients. The patients with CKD suffer from their premature myocardial infarctions or 
strokes, with all their terrible consequences; with the words from Dr Bright, still “a painful 
history”.  
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8 SVENSK SAMMANFATTNING 
Kronisk njursvikt innebär nedsatt förmåga av njurarna att rena blodet från slaggämnen och 
hålla vätskebalansen. Njursvikt är vanligt, det är en tyst folksjukdom utan mycket symtom i 
början, och mellan 10-15% av befolkningen är drabbad. Diabetes (”sockersjuka”), högt 
blodtryck och primära njursjukdomar s.k. .glomerulonefriter är de vanliga orsakerna till 
njursvikt i västvärlden. ”Brights disease” är ett äldre namn på glomerulonefrit. Dr Bright, 
njurmedicinens fader, beskrev redan i mitten av 1800-talet denna grupp av sjukdomar, som 
ofta ledde till allvarlig njursvikt, svårt långdraget lidande och död. Han noterade tecken på 
allvarlig hjärt-kärlsjukdom hos patienterna, och bedömde att detta måste ha något samband 
med själva njursjukdomen. 
Numera är det klarlagt att kronisk njursvikt är en stark riskfaktor för hjärt-kärlsjukdom i form 
av hjärtinfarkt och stroke, och att efter en hjärtkärlhändelse så har patienter med njursvikt 
sämre prognos. Det finns en rad riskfaktorer som bidrar, såsom rökning, fysisk inaktivitet, 
övervikt, diabetes, högt blodtryck som benämns traditionella riskfaktorer. Dessutom finns en 
rad riskfaktorer som är speciellt viktiga för patienter med njursvikt så som inflammation, 
oxidativ stress och kalk-fosfat rubbningar. Även låggradig inflammation i det innersta lagret 
av celler, endotelcellerna, som bekläder kärlväggarna s.k. endoteldysfunktion. Rubbningar i 
tarmflora har kommit upp som en tänkbar riskfaktor på senare år. Vid allvarligare njursvikt 
ansamlas en rad slaggprodukterna som samverkar med alla dessa riskfaktorer och ökar risken 
för hjärtkärlsjukdom. 
Rubbningar av blodets koagulationssystem är välkända bland njursvikts patienter, som både 
har en ökad risk för blodproppar och paradoxalt nog samtidigt en ökad risk för blödning. 
Blodplättar, trombocyter, är centrala i många hjärt-kärlsjukdomar. Deras uppgift är att stoppa 
den allra tidigaste blödningen, och aktivera koagulationssystemet. Det är blodplättarnas 
aktivering som skapar blodproppen som ger hjärtinfarkt eller stroke.  
Mikropartiklar är små cellstrukturer, med cellmembran, som knoppas av ifrån celler som 
aktiveras eller håller på att dö.  De cirkulerar i blodet, och bär samma ytproteiner och 
receptorer som sin ursprungscell. Mikropartiklar är både markörer för sjukdom, och överför 
även aktiverings och signaleringsämnen mellan celler. Mikropartiklar analyseras med 
flödescytometri, där man låter mikropartiklarna passera i en tunn kanal en efter en, och 
 62 
 
belyser dem med en laserstråle. Det ljus som reflekteras mäts, och beroende på ljusstyrkan 
och våglängden kan man klassificera och räkna antal mikropartiklar. Mikropartiklar från 
blodplättar är de vanligaste i cirkulationen, och koncentrationen av dessa korrelerar med en 
rad sjukdomar som njursvikt och hjärtkärlsjukdom. Mikropartiklar från endotelets celler 
korrelerar också med en rad sjukdomar, och kan ha en roll i endotelets funktion. D vitamin 
brist är mycket vanligt vid njursvikt, eftersom enzymet som aktiverar D-vitamin finns i 
njuren. Endoteldysfunktion är också vanligt bland njursviktspatienter. D-vitaminbrist har 
visats korrelera till endoteldysfunktion.  
Proteomic kallas en annan avancerad metod där man kan analysera en stor mängd proteiner 
samtidigt, flera hundra, i en mycket liten blodvolym.  
Det övergripande målet med det här doktorandprojektet var att klarlägga några av de 
mekanismer som kan orsaka att patienter med njursvikt har ökad risk för hjärt-kärlsjukdom, 
genom att undersöka koagulationsrubbningar och mikropartiklar, samt undersöka om olika 
koagulationsmarkörer kan förutsäga utfall i form av framtida hjärt-kärlhändelser. 
I den första studien visade vi att njursvikts patienter har en ökad koagulation jämfört med 
friska kontroller, på grund av en minskad förmåga att lösa upp blodproppen. Vi såg också en 
tätare organiserad blodproppstruktur på bilder med svepelektronmikroskop.  
I den andra studien visade vi att patienter med hjärtinfarkt och samtidig njursvikt har ökade 
koncentrationer av mikropartiklar än patienter utan njursvikt, vilket talar för en mer uttalad 
aktivering av blodplättarna och mer endoteldysfunktion.  
I den tredje studien gjorde vi en analys av prover insamlade vid en tidigare randomiserad 
kontrollerad studie, Solid studien. Den studien visade gynnsamma effekter av D-vitamin på 
endotelet. Vi visade att D-vitamin även minskade koncentrationen av mikropartiklar med 
markörer för inflammation. 
I den fjärde studien undersökte vi ett antal proteiner inblandade i blodkoagulation och 
endotel, i en stor grupp av patienter med hjärtinfarkt, och tittade på om de var relaterade till 
njursvikt. Proteiner som kan förutsäga utfall kan kallas biomarkörer. Flera av dessa var 
relaterade till njurfunktion, och där undersökte vi om dessa kunde förutsäga utfall som död, 
hjärtinfarkt, stroke eller hjärtsvikt. Det visade sig att om man jämförde grupper med eller utan 
njursvikt så var det olika proteiner som var associerade med dessa utfall.  
Det behövs omfattande framtida forskning för att bättre förstå dessa mekanismer och vad som 
kan göras åt dem. Både stora randomiserade studier över behandlingar, men även fler studier 
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för att klargöra vilken roll t.ex. mikropartiklar har i olika sjukdomar, och om man kan 
använda dessa för att t.ex. styra behandling. Andra viktiga områden är studier hur man ska 
förbättra det multidisciplinära omhändertagandet och teamarbetet med patienten, för 
förbättrad överlevnad och ökad livskvalitet.  
Patienter med njursvikt drabbas fortfarande ofta av hjärtinfarkt och stroke med hemska 
kvarstående men. Dr Bright beskrev njursviktspatientens kamp som “a painful history”. 
Framtida forskning har ett viktigt uppdrag att försöka minska hjärtkärlsjukdom hos dessa 
patienter.
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